The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[Epinephrine co-treated with [verlukast results in decreased activity of ABCC1 protein]] results in increased abundance of Glutathione Disulfide; [verlukast results in decreased activity of ABCC1 protein] which promotes the reaction and affects the abundance of Epinephrine metabolite ABCC1 protein results in increased export of Epinephrine metabolite
Sildenafil Citrate inhibits the reaction [Epinephrine results in decreased expression of ADIPOQ protein]; Tadalafil inhibits the reaction [Epinephrine results in decreased expression of ADIPOQ protein]
[Epinephrine binds to and results in increased activity of ADRA1A protein] which results in increased transport of Calcium; Epinephrine binds to and results in increased activity of ADRA1A protein Epinephrine results in increased activity of ADRA1A protein [Epinephrine binds to and results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium]; Epinephrine binds to and results in increased activity of ADRA1A protein; Epinephrine inhibits the reaction [ADRA1A protein binds to Prazosin]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1A protein] which results in increased abundance of Calcium] Epinephrine binds to ADRA1A protein
[Epinephrine binds to and results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]; Epinephrine binds to and results in increased activity of ADRA1B protein; Epinephrine inhibits the reaction [ADRA1B protein binds to Prazosin]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1B protein] which results in increased abundance of Calcium]
Epinephrine binds to ADRA1D protein Epinephrine results in increased activity of ADRA1D protein [Epinephrine binds to and results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; [Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; Carvedilol inhibits the reaction [[Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]; Epinephrine binds to and results in increased activity of ADRA1D protein; Epinephrine inhibits the reaction [ADRA1D protein binds to Prazosin]; Phentolamine inhibits the reaction [[Epinephrine results in increased activity of ADRA1D protein] which results in increased abundance of Calcium]
Epinephrine results in increased activity of ADRA2A protein Epinephrine promotes the reaction [GNB2 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNB4 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG12 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG2 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG3 protein binds to ADRA2A protein]; Epinephrine promotes the reaction [GNG4 protein binds to ADRA2A protein] [Epinephrine binds to and results in increased activity of ADRA2A protein] which results in increased abundance of Calcium; ADRA2A promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine binds to and results in increased activity of ADRA2A protein; Epinephrine inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]
[Epinephrine binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium; ADRA2B promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine binds to and results in increased activity of ADRA2B protein; Epinephrine inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]
[Epinephrine binds to and results in increased activity of ADRA2C protein] which results in increased abundance of Calcium; ADRA2C promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine binds to and results in increased activity of ADRA2C protein; Epinephrine inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]
[CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased activity of Epinephrine Epinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein] [Epinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; Epinephrine binds to and results in increased activity of ADRB1 protein; Epinephrine inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Epinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]
[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; Atenolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Atenolol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; carvedilol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; Epinephrine binds to and results in increased activity of ADRB2 protein; Epinephrine inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Epinephrine promotes the reaction [GRK2 protein results in increased phosphorylation of ADRB2 protein]; Epinephrine promotes the reaction [GRK5 protein results in increased phosphorylation of ADRB2 protein]; Epinephrine results in increased phosphorylation of and results in increased localization of ADRB2 protein; ICI 118551 inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; ICI 118551 inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein]; Propranolol inhibits the reaction [[Epinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP]; Propranolol inhibits the reaction [Epinephrine binds to and results in increased activity of ADRB2 protein] [Epinephrine results in increased activity of ADRB2 protein] which results in increased secretion of Histamine ADRB2 affects the susceptibility to Epinephrine
Epinephrine binds to and results in increased activity of ADRB3 protein [Epinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Epinephrine binds to and results in increased activity of ADRB3 protein; Epinephrine inhibits the reaction [cyanopindolol binds to ADRB3 protein]
Epinephrine results in decreased expression of AK2 protein [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of AK2 protein
Cycloheximide inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]; Dactinomycin inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]; Timolol inhibits the reaction [Epinephrine results in increased activity of AOC1 protein]
[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of C1QBP protein Epinephrine results in increased expression of C1QBP protein
Atenolol inhibits the reaction [Epinephrine results in increased activity of CASP3 protein]; carvedilol inhibits the reaction [Epinephrine results in increased activity of CASP3 protein] Epinephrine results in increased expression of CASP3 protein Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of CASP3 protein]; Sildenafil Citrate inhibits the reaction [Epinephrine results in increased expression of CASP3 protein]; Tadalafil inhibits the reaction [Epinephrine results in increased expression of CASP3 protein]; Vardenafil Dihydrochloride inhibits the reaction [Epinephrine results in increased expression of CASP3 protein]
Epinephrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 mRNA]; Epinephrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein]; Propranolol inhibits the reaction [Epinephrine inhibits the reaction [lipopolysaccharide, Escherichia coli O111 B4 results in increased expression of CCL3 protein]] Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Epinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Epinephrine inhibits the reaction [Thioglycolates results in increased secretion of CCL3 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; 2-methoxyidazoxan inhibits the reaction [Epinephrine results in increased expression of CCND1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased expression of CCND1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased expression of CCND1 protein]; Niclosamide inhibits the reaction [Epinephrine results in increased expression of CCND1 mRNA] Epinephrine results in increased expression of CCND1 mRNA; Epinephrine results in increased expression of CCND1 protein ADRA2A promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased expression of CCND1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased expression of CCND1 protein]
[methyllycaconitine binds to and results in decreased activity of CHRNA7 protein] inhibits the reaction [Nicotine results in increased abundance of Epinephrine]
COMT protein results in increased methylation of Epinephrine [COMT protein results in increased methylation of Epinephrine] which results in increased abundance of Metanephrine; tolcapone inhibits the reaction [[COMT protein results in increased methylation of Epinephrine] which results in increased abundance of Metanephrine] [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Epinephrine
ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein] 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; Dietary Fats promotes the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; Epinephrine promotes the reaction [Dietary Fats results in increased phosphorylation of CREB1 protein]; Ketoconazole inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased phosphorylation of CREB1 protein]
corticotropin releasing hormone (9-41) inhibits the reaction [CRH protein affects the abundance of Epinephrine] CRH results in increased abundance of Epinephrine
CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]; Isoproterenol inhibits the reaction [CSK protein promotes the reaction [Epinephrine results in increased abundance of Cyclic AMP]]
Epinephrine results in increased phosphorylation of CTNNB1 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Epinephrine results in increased phosphorylation of CTNNB1 protein]; Niclosamide inhibits the reaction [Epinephrine results in increased phosphorylation of CTNNB1 protein]
[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of CYCS protein Epinephrine results in increased expression of CYCS protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DES protein Epinephrine results in decreased expression of DES protein
Epinephrine affects the expression of FABP3 protein [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of FABP3 protein
Atenolol inhibits the reaction [Epinephrine results in increased expression of FAS protein]; carvedilol inhibits the reaction [Epinephrine results in increased expression of FAS protein]
Atenolol inhibits the reaction [Epinephrine results in increased expression of FASLG protein]; carvedilol inhibits the reaction [Epinephrine results in increased expression of FASLG protein]
Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] affects the localization of HSF1 protein] Epinephrine affects the localization of HSF1 protein
Epinephrine results in decreased expression of HSPB6 protein [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPB6 protein
Epinephrine results in decreased expression of IDH2 protein [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of IDH2 protein
Epinephrine results in decreased expression of IL6 mRNA Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
INS1 inhibits the reaction [Epinephrine results in increased expression of AQP7 mRNA] cilostamide inhibits the reaction [INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]]; Cytochalasin B inhibits the reaction [INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]]; hydroxy-2-naphthalenyl-methyl phosphonic acid trisacetoxymethylester inhibits the reaction [INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]]; INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]; Wortmannin inhibits the reaction [INS1 protein inhibits the reaction [Epinephrine results in increased transport of Fatty Acids, Nonesterified]]
[Epinephrine co-treated with INS protein] results in increased phosphorylation of AKT1 protein; Butoxamine inhibits the reaction [Epinephrine results in decreased expression of INS protein]; Pentolinium Tartrate inhibits the reaction [Epinephrine results in decreased secretion of INS protein]; Propranolol inhibits the reaction [Epinephrine results in decreased expression of INS protein]
Theophylline inhibits the reaction [Epinephrine results in increased activity of LIPE protein] Epinephrine results in increased expression of LIPE mRNA Epinephrine affects the localization of LIPE protein
ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein]; Epinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK1 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Epinephrine results in increased phosphorylation of MAPK1 protein] Epinephrine deficiency results in increased activity of MAPK1 protein Epinephrine affects the activity of MAPK1 protein
ADRA2A promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; ADRA2B promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; ADRA2C promotes the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein]; Epinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK3 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Epinephrine results in increased phosphorylation of MAPK3 protein] Epinephrine deficiency results in increased activity of MAPK3 protein Epinephrine affects the activity of MAPK3 protein
Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of [RELA protein binds to NFKB1 protein]]; Epinephrine results in increased activity of [RELA protein binds to NFKB1 protein]
Atenolol inhibits the reaction [Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Prazosin inhibits the reaction [Epinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] Epinephrine results in increased expression of NOS2 mRNA
[Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of PHB1 protein Epinephrine results in increased expression of PHB1 protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PKM protein Epinephrine results in increased expression of PKM protein
Epinephrine results in decreased expression of PPP2R1A protein [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PPP2R1A protein
[Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PRDX6 protein Epinephrine results in decreased expression of PRDX6 protein
Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of [RELA protein binds to NFKB1 protein]]; Epinephrine results in increased activity of [RELA protein binds to NFKB1 protein]
[Corticosterone results in decreased activity of SLC22A3 protein] inhibits the reaction [Epinephrine results in increased abundance of Epinephrine metabolite]; [Corticosterone results in decreased activity of SLC22A3 protein] which results in decreased abundance of Epinephrine SLC22A3 protein results in increased uptake of Epinephrine
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Epinephrine results in increased activity of SOD1 protein]; Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD1 protein]; Vitamin E inhibits the reaction [Epinephrine results in increased activity of SOD1 protein] Epinephrine binds to SOD1 protein mutant form [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of SOD1 protein Epinephrine results in increased expression of SOD1 protein Epinephrine results in increased expression of SOD1 mRNA; Epinephrine results in increased expression of SOD1 protein
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [Epinephrine results in increased activity of SOD2 protein]; Atenolol inhibits the reaction [Epinephrine results in increased activity of SOD2 protein]; Vitamin E inhibits the reaction [Epinephrine results in increased activity of SOD2 protein] [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of SOD2 protein Epinephrine results in increased expression of SOD2 protein Epinephrine results in increased expression of SOD2 mRNA; Epinephrine results in increased expression of SOD2 protein
TH protein results in increased chemical synthesis of Epinephrine [Clonidine results in increased expression of TH protein] which results in increased abundance of Epinephrine
Epinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of TNF protein] Epinephrine results in decreased expression of TNF mRNA Epinephrine results in decreased secretion of TNF protein
Epinephrine results in increased expression of VDAC1 protein [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of VDAC1 protein
[Epinephrine co-treated with Xanthine co-treated with XDH] affects the expression of MYL2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of AK2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DES protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of DLAT protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of ECHS1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of ETFB protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of FABP3 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HADH protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSP90AB1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPA9 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of HSPB6 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of IDH2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PKM protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PPP2R1A protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of PRDX6 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in decreased expression of SOD2 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of C1QBP protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of CYCS protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of HSPA5 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of PHB1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of SOD1 protein; [Epinephrine co-treated with Xanthine co-treated with XDH] results in increased expression of VDAC1 protein; Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] affects the localization of HSF1 protein]; Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of [RELA protein binds to NFKB1 protein]]; Epinephrine promotes the reaction [[Xanthine co-treated with XDH protein] results in increased activity of CASP3 protein]
11-nor-delta(9)-tetrahydrocannabinol-9-carboxylic acid inhibits the reaction [Norepinephrine results in increased activity of AANAT protein]; Cannabidiol inhibits the reaction [Norepinephrine results in increased activity of AANAT protein]; Cannabinol inhibits the reaction [Norepinephrine results in increased activity of AANAT protein]
Norepinephrine results in increased expression of ACTA2 mRNA [Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of ACTA2 mRNA]; Carnosine inhibits the reaction [Norepinephrine results in increased expression of ACTA2 mRNA]; FPS-ZM1 inhibits the reaction [Norepinephrine results in increased expression of ACTA2 mRNA]
[ADA protein co-treated with Norepinephrine] results in increased secretion of Glycerol Propranolol promotes the reaction [ADA protein results in decreased susceptibility to Norepinephrine]
Norepinephrine binds to ADRA1A protein [Norepinephrine binds to and results in increased activity of ADRA1A protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA1A protein; Norepinephrine inhibits the reaction [ADRA1A protein binds to Prazosin] Norepinephrine results in increased activity of ADRA1A protein 5-methylurapidil inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; [chlorethylclonidine co-treated with Phenoxybenzamine] inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; BMY 7378 inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; chlorethylclonidine inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; Phenoxybenzamine inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; Prazosin inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein]; Spiperone inhibits the reaction [Norepinephrine results in increased activity of ADRA1A protein] Norepinephrine affects the expression of ADRA1A protein ADRA1A protein affects the susceptibility to Norepinephrine
[Norepinephrine binds to and results in increased activity of ADRA1B protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA1B protein; Norepinephrine inhibits the reaction [ADRA1B protein binds to Prazosin]
Norepinephrine binds to ADRA1D protein [Norepinephrine binds to and results in increased activity of ADRA1D protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA1D protein; Norepinephrine inhibits the reaction [ADRA1D protein binds to Prazosin] ADRA1D affects the susceptibility to Norepinephrine Norepinephrine binds to and affects the activity of ADRA1D protein
ADRA2A protein affects the secretion of Norepinephrine [ADRA2A protein mutant form co-treated with ADRA2C protein mutant form] results in increased abundance of Norepinephrine ADRA2A protein affects the abundance of Norepinephrine 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; [Norepinephrine binds to and results in increased activity of ADRA2A protein] which results in increased abundance of Calcium; Brimonidine Tartrate inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Dexmedetomidine inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Doxazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Norepinephrine binds to and results in increased activity of ADRA2A protein; Norepinephrine inhibits the reaction [ADRA2A protein binds to 2-methoxyidazoxan]; Prazosin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; talipexole inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Thapsigargin inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein]; Yohimbine inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRA2A protein] Norepinephrine binds to ADRA2A protein [BRL 44408 binds to and results in decreased activity of ADRA2A protein] inhibits the reaction [Xylazine inhibits the reaction [Potassium results in increased secretion of Norepinephrine]]
[Norepinephrine binds to and results in increased activity of ADRA2B protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA2B protein; Norepinephrine inhibits the reaction [ADRA2B protein binds to 2-methoxyidazoxan]
Norepinephrine binds to ADRA2C protein [ADRA2A protein mutant form co-treated with ADRA2C protein mutant form] results in increased abundance of Norepinephrine [Norepinephrine binds to and results in increased activity of ADRA2C protein] which results in increased abundance of Calcium; Norepinephrine binds to and results in increased activity of ADRA2C protein; Norepinephrine inhibits the reaction [ADRA2C protein binds to 2-methoxyidazoxan]
[Norepinephrine binds to and results in increased activity of ADRB1 protein] which results in increased abundance of Cyclic AMP; Norepinephrine binds to and results in increased activity of ADRB1 protein; Norepinephrine inhibits the reaction [cyanopindolol binds to ADRB1 protein]; Norepinephrine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Norepinephrine promotes the reaction [ADRB1 protein results in increased activity of GNAS protein]; Octopamine inhibits the reaction [Norepinephrine binds to ADRB1 protein]; Propranolol inhibits the reaction [Norepinephrine binds to and results in increased activity of ADRB1 protein] [CGP 20712A binds to and results in decreased activity of ADRB1 protein] which results in decreased activity of Norepinephrine
[ICI 118551 binds to and results in decreased activity of ADRB2 protein] inhibits the reaction [Fenoterol affects the abundance of Norepinephrine] [Norepinephrine binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Cyclic AMP; Norepinephrine binds to and results in increased activity of ADRB2 protein; Norepinephrine inhibits the reaction [cyanopindolol binds to ADRB2 protein]; Octopamine inhibits the reaction [Norepinephrine binds to ADRB2 protein]; Propranolol inhibits the reaction [Norepinephrine binds to ADRB2 protein]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine binds to ADRB2 protein]
[Norepinephrine binds to and results in increased activity of ADRB3 protein] which results in increased abundance of Cyclic AMP; Norepinephrine binds to and results in increased activity of ADRB3 protein; Norepinephrine inhibits the reaction [cyanopindolol binds to ADRB3 protein]; Octopamine inhibits the reaction [Norepinephrine binds to ADRB3 protein] Norepinephrine results in increased activity of ADRB3 protein 3-(2-ethylphenoxy)-1-(1,2,3,4-tetrahydronaphth-1-ylamino)-2-propanol oxalate inhibits the reaction [Norepinephrine results in increased activity of ADRB3 protein]; Norepinephrine binds to and results in increased activity of ADRB3 protein
AGT protein results in increased abundance of Norepinephrine Norepinephrine affects the abundance of AGT protein carvedilol inhibits the reaction [AGT protein results in increased abundance of Norepinephrine]; Losartan inhibits the reaction [AGT protein results in increased abundance of Norepinephrine]
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA
N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in increased expression of BAX protein] Norepinephrine results in increased expression of BAX mRNA; Norepinephrine results in increased expression of BAX protein
Acetylcysteine inhibits the reaction [Norepinephrine results in decreased expression of BCL2 protein]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in decreased expression of BCL2 protein]
CALCA protein affects the susceptibility to Norepinephrine CALCA protein results in increased abundance of Norepinephrine Propranolol promotes the reaction [CALCA protein affects the susceptibility to Norepinephrine]
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP2 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP2 protein]
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of and results in increased cleavage of CASP3 protein]; Norepinephrine results in increased activity of and results in increased cleavage of CASP3 protein Norepinephrine results in increased activity of CASP3 protein Norepinephrine results in increased cleavage of CASP3 protein Norepinephrine results in increased expression of CASP3 protein Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP3 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP3 protein]; N-(1-methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea inhibits the reaction [Norepinephrine results in increased expression of CASP3 protein]; Norepinephrine inhibits the reaction [Okadaic Acid results in increased activity of CASP3 protein]
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP6 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP6 protein]
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of and results in increased cleavage of CASP7 protein]; Norepinephrine results in increased activity of and results in increased cleavage of CASP7 protein
Acetylcysteine inhibits the reaction [Norepinephrine results in increased activity of CASP9 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased activity of CASP9 protein] Norepinephrine affects the activity of CASP9 protein Norepinephrine results in increased cleavage of CASP9 protein
Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL3 mRNA]; Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]; Norepinephrine inhibits the reaction [Thioglycolates results in increased secretion of CCL3 protein]; Propranolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased secretion of CCL3 protein]]
Norepinephrine results in increased secretion of CCL5 protein Prazosin inhibits the reaction [Norepinephrine results in increased secretion of CCL5 protein]
carvedilol inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA]; Doxazosin inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA] [Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA]; FPS-ZM1 inhibits the reaction [Norepinephrine results in increased expression of COL1A1 mRNA]
Norepinephrine results in increased expression of COL3A1 mRNA [Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA]; Carnosine inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA]; FPS-ZM1 inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA] carvedilol inhibits the reaction [Norepinephrine results in increased expression of COL3A1 mRNA]
[tolcapone results in decreased activity of COMT protein] which results in increased abundance of Norepinephrine COMT protein results in increased methylation of Norepinephrine
corticotropin releasing hormone (9-41) inhibits the reaction [CRH protein affects the abundance of Norepinephrine]; Norepinephrine affects the expression of and affects the secretion of CRH protein; Propranolol affects the reaction [Norepinephrine affects the expression of and affects the secretion of CRH protein]; Yohimbine affects the reaction [Norepinephrine affects the expression of and affects the secretion of CRH protein] CRH results in increased abundance of Norepinephrine
[CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Morphine deficiency affects the abundance of Norepinephrine]; [CP 154526 binds to and results in decreased activity of CRHR1 protein] inhibits the reaction [Naloxone affects the abundance of Norepinephrine]
DBH gene polymorphism affects the abundance of Norepinephrine DBH protein results in increased abundance of Norepinephrine DBH mutant form results in decreased abundance of Norepinephrine
Norepinephrine inhibits the reaction [Rotenone results in decreased expression of DRD1 mRNA]; Norepinephrine inhibits the reaction [Rotenone results in decreased expression of DRD1 protein]
[Norepinephrine binds to and results in increased activity of DRD2 protein alternative form] which results in decreased transport of Calcium; Sulpiride inhibits the reaction [[Norepinephrine binds to and results in increased activity of DRD2 protein alternative form] which results in decreased transport of Calcium] Norepinephrine inhibits the reaction [Rotenone results in increased expression of DRD2 mRNA]; Norepinephrine inhibits the reaction [Rotenone results in increased expression of DRD2 protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; [EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine; BQ 610 inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; BQ 788 inhibits the reaction [EDN1 protein results in decreased secretion of Norepinephrine]; BQ 788 inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; KT 5823 inhibits the reaction [EDN1 protein results in decreased secretion of Norepinephrine]; Metoprolol inhibits the reaction [Norepinephrine results in increased expression of EDN1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [EDN1 protein results in increased secretion of Norepinephrine]; Picrotoxin inhibits the reaction [EDN1 protein results in decreased secretion of Norepinephrine] Norepinephrine results in increased activity of EDN1 promoter
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [EDN3 protein results in increased secretion of Norepinephrine]; 2-aminoethoxydiphenyl borate inhibits the reaction [EDN3 protein results in increased secretion of Norepinephrine]; [EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine; bisindolylmaleimide I inhibits the reaction [EDN3 protein results in increased secretion of Norepinephrine]; BQ 788 inhibits the reaction [EDN3 protein results in decreased secretion of Norepinephrine]; KT 5823 inhibits the reaction [EDN3 protein results in decreased secretion of Norepinephrine]; Picrotoxin inhibits the reaction [EDN3 protein results in decreased secretion of Norepinephrine]
[EDN1 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine; [EDN3 protein binds to and results in increased activity of EDNRB protein] which results in decreased secretion of Norepinephrine
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [EGF protein co-treated with Norepinephrine] results in increased expression of MYC mRNA
[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of ELK1 protein; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of ELK1 protein]
[Dexamethasone co-treated with Norepinephrine] results in increased expression of ELOVL3 mRNA; Dactinomycin inhibits the reaction [Norepinephrine results in increased expression of ELOVL3 mRNA]; Norepinephrine results in increased expression of and results in decreased degradation of ELOVL3 mRNA; rosiglitazone promotes the reaction [[Dexamethasone co-treated with Norepinephrine] results in increased expression of ELOVL3 mRNA]
Acetylcysteine inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; Norepinephrine promotes the reaction [REL protein binds to F3 promoter]; Norepinephrine promotes the reaction [RELA protein binds to F3 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; Vitamin E inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; KT 5720 inhibits the reaction [Norepinephrine inhibits the reaction [Carbachol results in increased expression of FGF1 protein]]; Norepinephrine inhibits the reaction [Carbachol results in increased expression of FGF1 protein]
[AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]
[Norepinephrine co-treated with Prazosin] results in decreased expression of FN1 protein; [Norepinephrine co-treated with Propranolol] results in increased expression of FN1 protein
Norepinephrine results in increased expression of FOS mRNA Norepinephrine results in increased expression of FOS; Norepinephrine results in increased expression of FOS mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; bisindolylmaleimide inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of FOS mRNA]; Tetradecanoylphorbol Acetate promotes the reaction [Norepinephrine results in increased expression of FOS mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of FOXO3 protein]; SHC1 protein affects the reaction [Norepinephrine results in increased phosphorylation of FOXO3 protein]
Norepinephrine results in increased activity of G6PD mRNA; Norepinephrine results in increased activity of G6PD protein Metoprolol inhibits the reaction [Norepinephrine results in increased activity of G6PD protein]; Prazosin inhibits the reaction [Norepinephrine results in increased activity of G6PD protein] Norepinephrine results in increased expression of G6PD mRNA
Propranolol inhibits the reaction [Norepinephrine results in increased expression of HMOX1 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased expression of HMOX1 mRNA]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]]; Acetylcysteine inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]; Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]; Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Vitamin E inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; wortmannin inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]]
Norepinephrine affects the secretion of IL1B protein Norepinephrine results in increased expression of IL1B mRNA carvedilol inhibits the reaction [Norepinephrine results in increased expression of IL1B mRNA]; Norepinephrine promotes the reaction [IL1B protein results in increased expression of IL6 protein]
Norepinephrine results in increased expression of and results in increased secretion of IL6 protein; sulforaphane inhibits the reaction [Norepinephrine results in increased expression of and results in increased secretion of IL6 protein] Norepinephrine results in increased expression of IL6 mRNA; Norepinephrine results in increased expression of IL6 protein Norepinephrine results in increased activity of IL6 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; Carvedilol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; ICI 118551 inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; Metoprolol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA]; Norepinephrine promotes the reaction [IL1B protein results in increased expression of IL6 protein]; Norepinephrine promotes the reaction [TNF protein results in increased expression of IL6 protein]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of IL6 mRNA] Norepinephrine results in decreased secretion of IL6 protein ANXA1 affects the reaction [Norepinephrine results in decreased secretion of IL6 protein]
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of JUN protein]; bisindolylmaleimide inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; bisindolylmaleimide inhibits the reaction [Norepinephrine results in increased phosphorylation of JUN protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of JUN mRNA]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased phosphorylation of JUN protein]; Tetradecanoylphorbol Acetate promotes the reaction [Norepinephrine results in increased expression of JUN mRNA] Norepinephrine results in increased expression of JUN; Norepinephrine results in increased expression of JUN mRNA
Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein; Phenoxybenzamine inhibits the reaction [Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein]; Piperoxan inhibits the reaction [Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein]; Prazosin inhibits the reaction [Norepinephrine results in decreased secretion of and results in decreased expression of LHB protein]
Prazosin inhibits the reaction [Norepinephrine results in increased expression of LPL mRNA]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of LPL mRNA]
Norepinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK1 protein] Norepinephrine results in increased phosphorylation of MAPK1 protein 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK1 protein]; AG 1879 inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK1 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK1 protein]; 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; [Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK1 protein]; Cadmium Chloride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; cadmium sulfate inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Carvedilol inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK1 protein]; diphenyleneiodonium inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; N,N'-bis(salicylideneamino)ethane-manganese(II) inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK1 protein; oxophenylarsine inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Prazosin affects the reaction [Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK1 protein]; Prazosin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK1 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK1 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK1 protein]
Norepinephrine inhibits the reaction [Estradiol results in decreased phosphorylation of MAPK3 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK3 protein] 1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK3 protein]; 4-(2-aminoethyl)benzenesulfonylfluoride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; 4-amino-5-(4-methylphenyl)-7-(tert-butyl)pyrazolo(3,4-d)pyrimidine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; [Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein; [Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein; AG 1879 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased phosphorylation of MAPK3 protein]; Cadmium Chloride inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; cadmium sulfate inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Carvedilol inhibits the reaction [Norepinephrine results in increased phosphorylation of MAPK3 protein]; diphenyleneiodonium inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Egtazic Acid inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Gadolinium inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; Mn(III) 5,10,15,20-tetrakis(N-methylpyridinium-2-yl)porphyrin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; N,N'-bis(salicylideneamino)ethane-manganese(II) inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; N-(8-aminooctyl)-5-iodonaphthalene-1-sulfonamide inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]; Norepinephrine results in increased activity of and results in increased phosphorylation of MAPK3 protein; oxophenylarsine inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Prazosin inhibits the reaction [[Norepinephrine co-treated with Propranolol] results in increased phosphorylation of MAPK3 protein]; Trifluoperazine inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of MAPK3 protein]; W 7 inhibits the reaction [[Norepinephrine co-treated with Timolol] results in increased activity of and results in increased phosphorylation of MAPK3 protein]
Cromolyn Sodium inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; Metoprolol inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; Norepinephrine results in increased activity of and results in increased expression of MMP2 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; trans-sodium crocetinate inhibits the reaction [Norepinephrine results in increased activity of MMP2 protein]; trans-sodium crocetinate inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA] Propranolol inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]; SB 203580 inhibits the reaction [Norepinephrine results in increased expression of MMP2 mRNA]
trans-sodium crocetinate inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA] Norepinephrine results in increased activity of MMP9 protein N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; Propranolol inhibits the reaction [Norepinephrine results in increased activity of MMP9 protein]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased activity of MMP9 protein]; quercetin 3-O-glucuronide inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; SR 11302 inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]; tanshinone inhibits the reaction [Norepinephrine results in increased expression of MMP9 mRNA]
PRKD1 protein affects the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein] chelerythrine inhibits the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein]; CRT 0066101 inhibits the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein]; fasudil inhibits the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein]
Acetylcysteine inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; Ascorbic Acid inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Norepinephrine affects the localization of [NFKB1 protein binds to RELA protein]; Norepinephrine promotes the reaction [[NFKB1 protein binds to RELA protein] which binds to SOD2 promoter]; Norepinephrine promotes the reaction [NFKB1 protein binds to ICAM1 promoter]; Norepinephrine results in increased activity of [NFKB1 protein binds to RELA protein]; prolinedithiocarbamate inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]; Vitamin E inhibits the reaction [Norepinephrine affects the localization of NFKB1 protein]
[GW 274150 results in decreased activity of NOS2 protein] which results in increased susceptibility to Norepinephrine; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Prazosin inhibits the reaction [Norepinephrine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Norepinephrine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] NOS2 protein affects the susceptibility to Norepinephrine
Norepinephrine results in increased expression of NPPA mRNA 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; Carvedilol inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of NPPA mRNA]; Propranolol promotes the reaction [Norepinephrine results in increased expression of NPPA mRNA]
[dextrallorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Methadone binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRD1 protein] which results in decreased uptake of Norepinephrine; [Tramadol binds to OPRD1 protein] which results in decreased uptake of Norepinephrine
[dextrallorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Methadone binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRK1 protein] which results in decreased uptake of Norepinephrine; [Tramadol binds to OPRK1 protein] which results in decreased uptake of Norepinephrine
[dextrallorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextromethorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextropropoxyphene binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Dextrorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Levallorphan binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Levorphanol binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Methadone binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Methadyl Acetate binds to OPRM1 protein] which results in decreased uptake of Norepinephrine; [Tramadol binds to OPRM1 protein] which results in decreased uptake of Norepinephrine
carvedilol inhibits the reaction [Norepinephrine results in increased activity of PGD mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased activity of PGD protein]
Norepinephrine results in increased activity of PLCB1 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCB1 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCB1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB1 protein]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCB1 mRNA] Norepinephrine results in increased expression of PLCB1 mRNA; Norepinephrine results in increased expression of PLCB1 protein
Norepinephrine results in increased activity of PLCB3 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCB3 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCB3 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCB3 protein]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCB3 mRNA] Norepinephrine results in increased expression of PLCB3 mRNA; Norepinephrine results in increased expression of PLCB3 protein
Norepinephrine results in increased activity of PLCD1 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCD1 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCD1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCD1 protein]; pyrazolanthrone inhibits the reaction [Norepinephrine results in increased expression of PLCD1 mRNA] Norepinephrine results in increased expression of PLCD1 mRNA; Norepinephrine results in increased expression of PLCD1 protein
Norepinephrine results in increased activity of PLCG1 protein 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein]; Norepinephrine results in increased expression of and results in increased activity of PLCG1 protein; Prazosin inhibits the reaction [Norepinephrine results in increased expression of and results in increased activity of PLCG1 protein]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCG1 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of PLCG1 protein] Norepinephrine results in increased expression of PLCG1 mRNA; Norepinephrine results in increased expression of PLCG1 protein
[Propranolol co-treated with Prazosin] inhibits the reaction [Norepinephrine results in increased expression of PPARGC1A mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of PPARGC1A mRNA] Norepinephrine inhibits the reaction [Testosterone results in decreased expression of PPARGC1A mRNA]
Norepinephrine results in increased phosphorylation of PPP1R12A protein PRKD1 protein affects the reaction [Norepinephrine results in increased phosphorylation of PPP1R12A protein] CRT 0066101 inhibits the reaction [Norepinephrine results in increased phosphorylation of PPP1R12A protein]; fasudil inhibits the reaction [Norepinephrine results in increased phosphorylation of PPP1R12A protein]
Norepinephrine results in increased phosphorylation of PPP1R14A protein chelerythrine inhibits the reaction [Norepinephrine results in increased phosphorylation of PPP1R14A protein]
PRKD1 protein affects the reaction [Norepinephrine results in increased phosphorylation of MYL1 protein]; PRKD1 protein affects the reaction [Norepinephrine results in increased phosphorylation of PPP1R12A protein] CRT 0066101 inhibits the reaction [Norepinephrine results in increased phosphorylation of PRKD1 protein]
[Estradiol co-treated with Norepinephrine] results in decreased expression of PTEN mRNA; [Progesterone co-treated with Norepinephrine] results in increased expression of PTEN mRNA; Norepinephrine inhibits the reaction [Testosterone results in decreased expression of PTEN mRNA]
[N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide results in decreased activity of PTGS2 protein] which results in decreased susceptibility to Norepinephrine
Acetylcysteine inhibits the reaction [Norepinephrine affects the localization of REL protein]; Ascorbic Acid inhibits the reaction [Norepinephrine affects the localization of REL protein]; bisindolylmaleimide I inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]]; Norepinephrine promotes the reaction [REL protein binds to F3 promoter]; Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine affects the localization of REL protein]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; REL mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; Vitamin E inhibits the reaction [Norepinephrine affects the localization of REL protein]; wortmannin inhibits the reaction [Norepinephrine affects the localization of REL protein]; wortmannin inhibits the reaction [Norepinephrine promotes the reaction [REL protein binds to ICAM1 promoter]]
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Norepinephrine affects the localization of RELA protein]; 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole inhibits the reaction [Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]]; Acetylcysteine inhibits the reaction [Norepinephrine affects the localization of RELA protein]; Ascorbic Acid inhibits the reaction [Norepinephrine affects the localization of RELA protein]; Norepinephrine affects the localization of [NFKB1 protein binds to RELA protein]; Norepinephrine promotes the reaction [[NFKB1 protein binds to RELA protein] which binds to SOD2 promoter]; Norepinephrine promotes the reaction [RELA protein binds to F3 promoter]; Norepinephrine promotes the reaction [RELA protein binds to ICAM1 promoter]; Norepinephrine results in increased activity of [NFKB1 protein binds to RELA protein]; prolinedithiocarbamate inhibits the reaction [Norepinephrine affects the localization of RELA protein]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of F3 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of ICAM1 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Vitamin E inhibits the reaction [Norepinephrine affects the localization of RELA protein]
Norepinephrine results in increased expression of S100B mRNA; Norepinephrine results in increased expression of S100B protein S100B protein affects the susceptibility to Norepinephrine
carvedilol inhibits the reaction [Norepinephrine results in increased expression of SERPINH1 mRNA]; carvedilol inhibits the reaction [Norepinephrine results in increased expression of SERPINH1 protein] Norepinephrine results in increased expression of SERPINH1 mRNA; Norepinephrine results in increased expression of SERPINH1 protein
1,2-Dihydroxybenzene-3,5-Disulfonic Acid Disodium Salt inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; bisindolylmaleimide I inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; EGFR protein inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; Prazosin inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; RTKI cpd inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; SHC1 protein affects the reaction [Norepinephrine results in decreased expression of SOD2 protein]; SHC1 protein affects the reaction [Norepinephrine results in increased phosphorylation of FOXO3 protein]; Tetradecanoylphorbol Acetate inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]; U 0126 inhibits the reaction [Norepinephrine results in increased phosphorylation of SHC1 protein alternative form]
Norepinephrine inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin] Norepinephrine results in increased expression of SLC18A2 mRNA Norepinephrine results in decreased activity of SLC18A2 protein Norepinephrine binds to SLC18A2 protein
SLC22A3 protein results in increased uptake of Norepinephrine Norepinephrine affects the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium]
N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A2 protein results in increased uptake of Norepinephrine]; Norepinephrine inhibits the reaction [nisoxetine binds to SLC6A2 protein]; SLC6A2 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein] [Cullen corylifolium extract results in decreased activity of SLC6A2 protein] which results in decreased uptake of Norepinephrine; Norepinephrine affects the localization of and affects the metabolism of SLC6A2 protein [Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine; Bupivacaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]; Lidocaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine]; tricaine inhibits the reaction [[Desipramine results in decreased activity of SLC6A2 protein] which results in decreased abundance of Norepinephrine] Norepinephrine results in decreased expression of SLC6A2 protein SLC6A2 mutant form results in decreased uptake of Norepinephrine Norepinephrine results in decreased activity of SLC6A2 protein
SLC6A3 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein] SLC6A3 protein results in increased uptake of Norepinephrine
Norepinephrine results in decreased expression of SOD2 protein Norepinephrine results in increased expression of SOD2 mRNA Acetylcysteine inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; NFKB1 mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Norepinephrine promotes the reaction [[NFKB1 protein binds to RELA protein] which binds to SOD2 promoter]; prolinedithiocarbamate inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; RELA mutant form inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA]; Vitamin E inhibits the reaction [Norepinephrine results in increased expression of SOD2 mRNA] SHC1 protein affects the reaction [Norepinephrine results in decreased expression of SOD2 protein]
[Clorgyline co-treated with Selegiline] inhibits the reaction [Norepinephrine results in increased phosphorylation of STAT3 protein]; Carnosine inhibits the reaction [Norepinephrine results in increased phosphorylation of STAT3 protein]
SLC6A2 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]; SLC6A3 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]; SLC6A4 protein promotes the reaction [Norepinephrine results in increased activity of TAAR1 protein]
[Estradiol co-treated with Norepinephrine] results in decreased expression of TFAM mRNA; [Progesterone co-treated with Norepinephrine] results in increased expression of TFAM mRNA
Norepinephrine results in increased expression of TGFB2 mRNA; Norepinephrine results in increased expression of TGFB2 protein Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB2 mRNA]
Norepinephrine results in increased expression of TGFB3 mRNA Prazosin inhibits the reaction [Norepinephrine results in increased expression of TGFB3 mRNA]
[Clonidine results in decreased activity of and results in decreased expression of TH protein] which results in decreased abundance of Norepinephrine; [Clonidine results in increased expression of TH protein] which results in increased abundance of Norepinephrine TH protein results in increased chemical synthesis of Norepinephrine
Metoprolol inhibits the reaction [Norepinephrine results in increased expression of TIMP2 mRNA]; Prazosin inhibits the reaction [Norepinephrine results in increased expression of TIMP2 mRNA]
Acetylcysteine inhibits the reaction [Norepinephrine results in increased secretion of TNF protein]; Ascorbic Acid inhibits the reaction [Norepinephrine results in increased secretion of TNF protein]; Norepinephrine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; Norepinephrine promotes the reaction [TNF protein results in increased expression of IL6 protein] Norepinephrine results in increased expression of TNF mRNA
[Rosiglitazone results in increased susceptibility to Norepinephrine] which results in increased expression of UCP1 mRNA; [Rosiglitazone results in increased susceptibility to Norepinephrine] which results in increased expression of UCP1 protein; AG 1879 promotes the reaction [Norepinephrine results in increased expression of UCP1 mRNA] [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine inhibits the reaction [EGF protein results in decreased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF1 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine promotes the reaction [FGF2 protein results in increased expression of UCP1 mRNA]]; [AVP protein co-treated with Norepinephrine] inhibits the reaction [Triiodothyronine results in increased expression of UCP1 mRNA]; [EGF protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [FGF1 protein co-treated with AVP protein co-treated with Norepinephrine co-treated with Triiodothyronine] results in decreased expression of UCP1 mRNA; [Triiodothyronine co-treated with Norepinephrine] results in increased expression of UCP1 mRNA
USF1 gene polymorphism promotes the reaction [Norepinephrine results in increased metabolism of Lipids]; USF1 protein affects the reaction [Norepinephrine results in increased metabolism of Lipids]
[Cobalt co-treated with Norepinephrine] results in increased expression of VEGFA mRNA; [Cycloheximide co-treated with Norepinephrine] results in increased expression of VEGFA mRNA; [Norepinephrine co-treated with Tetradecanoylphorbol Acetate] results in increased expression of VEGFA mRNA; AG 1879 inhibits the reaction [Norepinephrine results in increased expression of VEGFA mRNA]; Cyclic AMP affects the reaction [Norepinephrine results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of VEGFA mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Norepinephrine results in increased expression of VEGFA]; Propranolol inhibits the reaction [Norepinephrine results in increased expression of VEGFA mRNA]
3-methoxytyramine results in increased activity of TAAR1 protein [3-methoxytyramine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP
3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein [3-hydroxy-4-methoxyphenethylamine results in increased activity of TAAR1 protein] which results in increased abundance of Cyclic AMP
ADRB1 gene affects the susceptibility to Dobutamine; ADRB1 gene polymorphism affects the susceptibility to Dobutamine; ADRB1 protein polymorphism affects the susceptibility to Dobutamine [Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 mRNA; [Dobutamine co-treated with ICI 118551] results in decreased expression of ADRB1 protein; Dobutamine binds to and results in increased activity of ADRB1 protein; Dobutamine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Oxygen deficiency results in increased susceptibility to [Dobutamine binds to and results in increased activity of ADRB1 protein] ADRB1 gene polymorphism affects the susceptibility to [Dobutamine co-treated with Metoprolol]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Dobutamine binds to and results in increased activity of ADRB1 protein; Dobutamine inhibits the reaction [Iodocyanopindolol binds to ADRB1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]
[Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 mRNA; [Dobutamine co-treated with ICI 118551] results in increased expression of ADRB3 protein
AKT1 protein affects the susceptibility to Dobutamine Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]
ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]
ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]
Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 mRNA]; Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of CCL2 protein]
EGFR gene mutant form results in decreased susceptibility to Dobutamine AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; AG 1879 inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of and results in increased uptake of EGFR protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]; Propranolol inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased uptake of EGFR protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]
Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]; Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]
HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; HBEGF protein promotes the reaction [Dobutamine promotes the reaction [ADRB1 protein results in increased phosphorylation of EGFR protein]]
esmolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]; Metoprolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 mRNA]; Metoprolol inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased expression of HMOX1 mRNA]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased expression of HMOX1 protein] Dobutamine results in increased expression of HMOX1 mRNA; Dobutamine results in increased expression of HMOX1 protein
Dobutamine inhibits the reaction [Tetradecanoylphorbol Acetate results in increased expression of IL10 protein] Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL10 protein]
Dobutamine results in increased expression of IL6 protein Dobutamine results in decreased expression of IL6 mRNA Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 mRNA]; Dobutamine inhibits the reaction [Lipopolysaccharides results in increased expression of IL6 protein]
Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]; Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]
Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]; Metoprolol inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [Dobutamine results in increased activity of [JUN protein binds to JUND protein binds to FOS protein]]
KCNJ11 protein affects the reaction [[Manganese co-treated with Dobutamine] results in increased abundance of Calcium] KCNJ11 protein affects the susceptibility to Dobutamine
Dobutamine results in decreased secretion of LEP protein Dobutamine results in decreased expression of LEP mRNA; Dobutamine results in decreased expression of LEP protein
[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK1 protein AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK1 protein]] Dobutamine results in increased phosphorylation of MAPK1 protein
[Dobutamine co-treated with ICI 118551] results in increased activity of MAPK3 protein AG 1879 inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB1 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; ARRB2 protein promotes the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]; HBEGF protein inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; N-(2(R)-2-(hydroxamidocarbonylmethyl)-4-methylpentanoyl)-L-tryptophan methylamide inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]]; RTKI cpd inhibits the reaction [Dobutamine promotes the reaction [[ADRB1 protein co-treated with EGFR protein] results in increased phosphorylation of MAPK3 protein]] Dobutamine results in increased phosphorylation of MAPK3 protein
Cycloheximide inhibits the reaction [Dobutamine results in increased secretion of REN protein]; Dactinomycin inhibits the reaction [Dobutamine results in increased secretion of REN protein] Dobutamine results in increased expression of REN mRNA Dobutamine results in increased activity of REN protein
USF1 gene polymorphism promotes the reaction [Dobutamine results in increased metabolism of Lipids]; USF1 protein affects the reaction [Dobutamine results in increased metabolism of Lipids]
[N(6)-cyclohexyladenosine binds to and results in increased activity of ADORA1 protein] promotes the reaction [Methamphetamine results in increased secretion of Dopamine]
[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Dopamine; ICI 118551 inhibits the reaction [[Terbutaline binds to and results in increased activity of ADRB2 protein] which results in increased abundance of Dopamine]
Clozapine inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]; Clozapine promotes the reaction [Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]]; Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]; Raclopride inhibits the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]; Raclopride promotes the reaction [Dopamine promotes the reaction [AGT protein results in increased secretion of Aldosterone]]
[[CVT-10216 results in decreased activity of ALDH2 protein] which results in increased abundance of Tetrahydropapaveroline] inhibits the reaction [Cocaine results in increased abundance of and results in increased secretion of Dopamine]; ALDH2 protein affects the reaction [Cocaine results in increased abundance of Dopamine]
Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]]
Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]]
[Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 protein
Dopamine results in decreased expression of BCL2 protein polydatin inhibits the reaction [Dopamine results in decreased expression of BCL2 protein]; Resveratrol inhibits the reaction [Dopamine results in decreased expression of BCL2 protein]
[Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 protein
[Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]
[Dopamine co-treated with Zinc deficiency] results in increased activity of CASP3 protein; Acetylcysteine inhibits the reaction [Dopamine results in increased activity of and results in increased cleavage of CASP3 protein]; Dopamine results in increased activity of and results in increased cleavage of CASP3 protein; Dopamine results in increased cleavage of and results in increased activity of CASP3 protein; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of CASP3 protein]; resveratrol inhibits the reaction [Dopamine results in increased cleavage of and results in increased activity of CASP3 protein] Dopamine results in increased activity of CASP3 protein SH-6 compound promotes the reaction [Dopamine results in increased activity of CASP3 protein]; SH-6 compound promotes the reaction [tanespimycin promotes the reaction [Dopamine results in increased activity of CASP3 protein]]; tanespimycin promotes the reaction [Dopamine results in increased activity of CASP3 protein]
Acetylcysteine inhibits the reaction [Dopamine results in increased activity of and results in increased cleavage of CASP7 protein]; Dopamine results in increased activity of and results in increased cleavage of CASP7 protein Dopamine results in increased activity of CASP7 protein
CAT protein inhibits the reaction [N-Methyl-3,4-methylenedioxyamphetamine results in decreased abundance of Dopamine] Dopamine results in increased expression of CAT mRNA [Dopamine co-treated with Dicumarol] results in increased expression of CAT mRNA
[pozanicline binds to and results in increased activity of [CHRNA6 protein binds to CHRNB2 protein]] which results in increased secretion of Dopamine; Nicotine inhibits the reaction [[CHRNA6 protein binds to CHRNB2 protein] which results in increased secretion of Dopamine]
[pozanicline binds to and results in increased activity of [CHRNA6 protein binds to CHRNB2 protein]] which results in increased secretion of Dopamine; Nicotine inhibits the reaction [[CHRNA6 protein binds to CHRNB2 protein] which results in increased secretion of Dopamine]
COMT protein results in increased methylation of Dopamine COMT protein results in increased metabolism of Dopamine [tolcapone results in decreased activity of COMT protein] promotes the reaction [Clozapine results in increased abundance of Dopamine]; COMT protein affects the reaction [Amphetamine results in increased abundance of Dopamine] 3,4-methylenedioxyethamphetamine inhibits the reaction [COMT protein results in increased methylation of Dopamine]; [entacapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine; [tolcapone results in decreased activity of COMT protein] which results in increased abundance of Dopamine; N-methyl-1-(1,3-benzodioxol-5-yl)-2-butanamine inhibits the reaction [COMT protein results in increased methylation of Dopamine]
[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein; Calcium promotes the reaction [Dopamine results in increased phosphorylation of CREB1 protein]; Dizocilpine Maleate inhibits the reaction [Dopamine results in increased phosphorylation of CREB1 protein]; Dopamine binds to and results in increased activity of CREB1 protein; KN 62 inhibits the reaction [Dopamine results in increased phosphorylation of CREB1 protein]; SCH 23390 inhibits the reaction [[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein]
Dopamine inhibits the reaction [Tetrachlorodibenzodioxin results in increased activity of CYP1A1 protein] Dopamine results in decreased activity of CYP1A1 protein
Dopamine results in decreased activity of CYP2D6 protein CYP2D6 protein results in increased abundance of Dopamine [CYP2D6 protein results in increased metabolism of Tyramine] which results in increased abundance of Dopamine
Dopamine binds to and results in increased activity of DRD1 protein; SCH 23390 inhibits the reaction [Dopamine affects the localization of DRD1 protein]; SCH 23390 inhibits the reaction [Dopamine results in increased activity of DRD1 protein] [alpha-pyrrolidinovalerophenone results in increased secretion of Dopamine] results in increased activity of [DRD1 protein co-treated with DRD2 protein] [Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein; [Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein; Dopamine deficiency inhibits the reaction [SCH 23390 binds to DRD1 protein]; DRD1 protein promotes the reaction [zonisamide affects the secretion of Dopamine]; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]; SCH 23390 inhibits the reaction [[Dopamine binds to and results in increased activity of DRD1 protein] which results in increased phosphorylation of CREB1 protein]
[Dopamine co-treated with DRD2 protein alternative form] results in increased activity of RHOA protein; [Dopamine co-treated with Raclopride] promotes the reaction [Dopamine binds to DRD2 protein]; Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]; Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]] [alpha-pyrrolidinovalerophenone results in increased secretion of Dopamine] results in increased activity of [DRD1 protein co-treated with DRD2 protein] DRD2 protein affects the susceptibility to Dopamine Dopamine results in increased activity of DRD2 protein [Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine; [Raclopride binds to and results in decreased activity of DRD2 protein] which results in increased abundance of Dopamine; [Remoxipride results in decreased activity of DRD2 protein] inhibits the reaction [Dopamine results in decreased susceptibility to Pilocarpine]; Clozapine promotes the reaction [Dopamine binds to DRD2 protein]; Cocaine promotes the reaction [[DRD2 protein results in increased phosphorylation of TH protein] which results in increased abundance of Dopamine]; cypermethrin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; DBH protein affects the reaction [Dopamine binds to DRD2 protein]; decamethrin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Dopamine promotes the reaction [Oxidopamine binds to DRD2 protein]; DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of IL10 protein]; DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of TGFB1 protein]; DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of VEGFA protein]; DRD2 mutant form inhibits the reaction [Dopamine results in increased expression of TNF protein]; DRD4 protein affects the reaction [Dopamine binds to DRD2 protein]; estradiol 3-benzoate inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Ethanol affects the reaction [Dopamine binds to DRD2 protein]; GRK6 protein affects the reaction [Dopamine binds to DRD2 protein]; Haloperidol inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Haloperidol promotes the reaction [Dopamine binds to DRD2 protein]; Olanzapine promotes the reaction [Dopamine binds to DRD2 protein]; Quetiapine Fumarate promotes the reaction [Dopamine binds to DRD2 protein]; Risperidone promotes the reaction [Dopamine binds to DRD2 protein]; Spiperone inhibits the reaction [Cocaine promotes the reaction [[DRD2 protein results in increased phosphorylation of TH protein] which results in increased abundance of Dopamine]]; tautomycin inhibits the reaction [[Quinpirole binds to and results in increased activity of DRD2 protein] which results in increased uptake of Dopamine]; Tea inhibits the reaction [Dopamine promotes the reaction [Oxidopamine binds to DRD2 protein]] Dopamine binds to DRD2 protein alternative form
Dopamine results in increased activity of DRD3 protein Butaclamol inhibits the reaction [Dopamine results in increased activity of DRD3 protein]; Dopamine binds to and results in increased activity of DRD3 protein; Endocannabinoids promotes the reaction [Dopamine binds to and results in increased activity of DRD3 protein] [Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; [Raclopride binds to and results in decreased activity of DRD3 protein] which results in increased abundance of Dopamine; DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]; DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]]
DRD4 protein affects the reaction [Dopamine binds to DRD2 protein] Dopamine binds to Drd4 protein Clozapine inhibits the reaction [Dopamine results in increased activity of DRD4 protein]; Dopamine binds to and results in increased activity of DRD4 protein; Endocannabinoids inhibits the reaction [Dopamine binds to and results in increased activity of DRD4 protein]
[EFHD2 gene mutant form affects the susceptibility to Ethanol] which results in increased secretion of Dopamine EFHD2 gene mutant form results in decreased secretion of Dopamine
[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; [EN1 protein co-treated with EN2 protein] results in increased abundance of Dopamine; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]
[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; [EN1 protein co-treated with EN2 protein] results in increased abundance of Dopamine; NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]
6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA; [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein; bisindolylmaleimide I inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein] Dopamine results in increased expression of FOS mRNA; Dopamine results in increased expression of FOS protein
Dopamine results in increased activity of G6PD protein Dopamine results in decreased activity of G6PD protein Atenolol inhibits the reaction [Dopamine results in increased activity of G6PD protein]
[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein; N-(2-(4-bromocinnamylamino)ethyl)-5-isoquinolinesulfonamide inhibits the reaction [[Dopamine results in increased activity of DRD1 protein] which results in increased phosphorylation of GRIN1 protein]
GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB1 protein]]; GRK2 protein promotes the reaction [Dopamine promotes the reaction [DRD2 protein affects the localization of ARRB2 protein]]
[6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Methamphetamine results in decreased abundance of Dopamine]; [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Methamphetamine results in increased secretion of Dopamine]; [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] inhibits the reaction [Veratridine results in increased secretion of Dopamine]; [6-methyl-2-(phenylethynyl)pyridine binds to and results in decreased activity of GRM5 protein] which results in decreased secretion of Dopamine
[1-(2-methylbenzoxazol-6-yl)-3-(1,5)naphthyridin-4-yl urea binds to and results in decreased activity of HCRTR1 protein] inhibits the reaction [Amphetamine results in increased secretion of Dopamine]
[Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BBC3 protein; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 mRNA; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of BNIP3 protein; [Dopamine results in increased expression of HIF1A protein] which results in increased expression of TP53 protein; Dopamine results in increased expression of HIF1A protein Clodronic Acid inhibits the reaction [Dopamine results in decreased expression of HIF1A protein]; eticlopride inhibits the reaction [Dopamine results in decreased expression of HIF1A protein]; zoledronic acid inhibits the reaction [Dopamine results in decreased expression of HIF1A protein] [Dopamine results in increased expression of HIF1A protein] which results in increased expression of and results in increased phosphorylation of TP53 protein; Acetylcysteine inhibits the reaction [Dopamine results in increased expression of HIF1A protein]
[Dopamine results in increased expression of HMOX1 mRNA] which results in increased expression of SOD2 mRNA; Dopamine results in increased expression of HMOX1 mRNA [SNCA protein co-treated with Dopamine] results in increased expression of HMOX1 protein; [SNCA protein co-treated with Paraquat co-treated with Dopamine] results in increased expression of HMOX1 protein; HMOX1 protein inhibits the reaction [1-Methyl-4-phenylpyridinium results in decreased abundance of Dopamine]
[1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene analog binds to and results in increased activity of HRH1 protein] promotes the reaction [TH protein results in increased chemical synthesis of Dopamine]
[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine; Cocaine promotes the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]; Ketanserin inhibits the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]; Ketanserin inhibits the reaction [Cocaine promotes the reaction [[4-iodo-2,5-dimethoxyphenylisopropylamine binds to and results in increased activity of HTR2A protein] which results in increased secretion of and results in increased abundance of Dopamine]]
Dopamine binds to and results in increased activity of [HTR3A protein binds to HTR3A protein]; Dopamine binds to and results in increased activity of [HTR3A protein binds to HTR3B protein]
Dopamine results in decreased expression of IL10 mRNA; Dopamine results in decreased expression of IL10 protein DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of IL10 protein]; eticlopride inhibits the reaction [Dopamine results in decreased expression of IL10 protein]
Dopamine promotes the reaction [Metoclopramide results in increased expression of INS protein] Dopamine results in increased secretion of INS protein Dopamine results in increased expression of INS protein
Dopamine results in increased phosphorylation of JUN protein PRKN protein inhibits the reaction [Dopamine results in increased phosphorylation of JUN protein]
MAOA mutant form results in increased abundance of Dopamine MAOA protein results in decreased amination of Dopamine 3,4-Methylenedioxyamphetamine inhibits the reaction [MAOA protein results in decreased amination of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [MAOA protein results in decreased amination of Dopamine]
[Ro 16-6491 results in decreased activity of MAOB protein] which results in decreased susceptibility to Dopamine; [Selegiline results in decreased activity of MAOB protein] which results in increased abundance of Dopamine MAOB protein results in increased degradation of Dopamine 1-(8-bromobenzo(1,2-b;4,5-b')difuran-4-yl)-2-aminopropane inhibits the reaction [MAOB protein results in increased degradation of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [MAOB protein results in decreased amination of Dopamine]; Selegiline inhibits the reaction [MAOB protein results in decreased amination of Dopamine]; Selegiline inhibits the reaction [MAOB protein results in increased degradation of Dopamine]
Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein; RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein] [Ionomycin co-treated with CAMK2A protein] inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]; DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK1 protein]]
Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein; RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein] DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]; NGB 2904 inhibits the reaction [DRD3 protein promotes the reaction [Dopamine results in increased phosphorylation of MAPK3 protein]]
Acetylcysteine inhibits the reaction [Dopamine results in increased phosphorylation of MAPK8 protein]; Glutathione inhibits the reaction [Dopamine results in increased phosphorylation of MAPK8 protein]
[MT1 co-treated with Dopamine] results in decreased abundance of semiquinone radicals; [MT1 gene mutant form co-treated with MT2 gene mutant form co-treated with Mercuric Chloride] results in decreased abundance of Dopamine
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Dopamine results in increased activity of MTR protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Dopamine results in increased activity of MTR protein]; Ethanol promotes the reaction [Dopamine results in increased activity of MTR protein]; wortmannin inhibits the reaction [Dopamine results in increased activity of MTR protein]
NDUFS1 mutant form inhibits the reaction [[EN1 protein co-treated with EN2 protein] inhibits the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]]
NDUFS4 protein affects the reaction [Rotenone results in increased abundance of Dopamine]; Paclitaxel inhibits the reaction [NDUFS4 protein affects the reaction [Rotenone results in increased abundance of Dopamine]]
Atenolol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Atenolol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; carvedilol inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; carvedilol inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]]; Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]; Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]; Prazosin inhibits the reaction [Dopamine inhibits the reaction [[Lipopolysaccharides results in increased expression of NOS2 protein] which results in increased abundance of Nitrites]]; Prazosin inhibits the reaction [Dopamine inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein]] Dopamine results in increased expression of NOS2 mRNA; Dopamine results in increased expression of NOS2 protein
NR3C1 protein results in increased abundance of Dopamine [RU 43044 binds to and results in decreased activity of NR3C1 protein] inhibits the reaction [Methamphetamine results in increased secretion of Dopamine]
Dopamine promotes the reaction [Zinc deficiency results in increased cleavage of PARP1 protein]; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein]; resveratrol inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein]; Zinc deficiency promotes the reaction [Dopamine results in increased cleavage of PARP1 protein] [PARP1 protein results in increased susceptibility to 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine] which results in increased abundance of Dopamine
1,3-dimethylthiourea inhibits the reaction [Dopamine results in decreased expression of PCMT1 mRNA]; Acetylcysteine inhibits the reaction [Dopamine results in decreased expression of PCMT1 mRNA]; Acetylcysteine inhibits the reaction [Dopamine results in decreased expression of PCMT1 protein] Dopamine results in decreased expression of PCMT1 mRNA; Dopamine results in decreased expression of PCMT1 protein
[PINK1 mutant form results in increased susceptibility to Paraquat] which results in decreased abundance of Dopamine; Paraquat affects the reaction [PINK1 protein affects the abundance of Dopamine]
[rottlerin results in decreased activity of PRKCD protein] inhibits the reaction [Methamphetamine results in increased metabolism of Dopamine]; PRKCD protein affects the reaction [Methamphetamine results in increased metabolism of Dopamine]
PRKN protein inhibits the reaction [Dopamine results in increased abundance of Reactive Oxygen Species]; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of CASP3 protein]; PRKN protein inhibits the reaction [Dopamine results in increased cleavage of PARP1 protein]; PRKN protein inhibits the reaction [Dopamine results in increased phosphorylation of JUN protein] PRKN mutant form results in increased abundance of and results in increased metabolism of Dopamine; PRKN protein affects the abundance of and affects the metabolism of Dopamine; PRKN protein promotes the reaction [Amphetamine results in increased abundance of Dopamine] Dopamine results in increased expression of PRKN mRNA
[Raloxifene Hydrochloride co-treated with Dopamine] results in decreased expression of PRL protein; Domperidone inhibits the reaction [Dopamine results in decreased expression of PRL protein] Haloperidol inhibits the reaction [Dopamine results in decreased secretion of PRL protein]; Risperidone inhibits the reaction [Dopamine results in decreased secretion of PRL protein]
RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein]; RGS3 protein affects the reaction [Dopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein]
Heptachlor Epoxide inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; para-methyl-4-methylaminorex inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; Reserpine inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine] DDT inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; Dichlorodiphenyldichloroethane inhibits the reaction [SLC18A2 protein results in increased uptake of Dopamine]; SLC18A2 protein affects the transport of and affects the abundance of Dopamine Dopamine inhibits the reaction [SLC18A2 protein results in increased uptake of Serotonin] Dopamine results in decreased activity of SLC18A2 protein Dopamine binds to SLC18A2 protein SLC18A2 results in decreased abundance of Dopamine
SLC22A3 protein results in increased uptake of Dopamine Dopamine affects the reaction [SLC22A3 protein results in increased uptake of Tetraethylammonium]; Dopamine inhibits the reaction [SLC22A3 protein results in increased uptake of 1-Methyl-4-phenylpyridinium]; Dopamine inhibits the reaction [SLC22A3 protein results in increased uptake of Dopamine]
Dactinomycin inhibits the reaction [Dopamine results in increased expression of SLC25A14 mRNA]; SLC25A14 protein inhibits the reaction [Dopamine results in increased abundance of Superoxides] SLC25A14 protein results in decreased susceptibility to Dopamine
Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein] SLC6A2 protein results in increased uptake of Dopamine
2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; 4-fluoroamphetamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; 4-methylaminorex inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA; [Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein; [SLC6A3 protein polymorphism affects the susceptibility to 2-(3-methoxyphenyl)-2-(ethylamino)cyclohexanone] which affects the uptake of Dopamine; [SLC6A3 protein polymorphism affects the susceptibility to Bupropion] which affects the uptake of Dopamine; [SLC6A3 protein polymorphism affects the susceptibility to Citalopram] which affects the uptake of Dopamine; [SLC6A3 protein polymorphism affects the susceptibility to Cocaine] which affects the uptake of Dopamine; [SLC6A3 protein polymorphism affects the susceptibility to Methylphenidate] which affects the uptake of Dopamine; [SNCA protein affects the localization of SLC6A3 protein] which affects the uptake of Dopamine; Amphetamine inhibits the reaction [SLC6A3 protein mutant form results in increased export of Dopamine]; Amphetamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Benztropine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; bisindolylmaleimide I inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Bupropion inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Bupropion inhibits the reaction [SLC6A3 protein mutant form results in decreased import of Dopamine]; Bupropion inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Bupropion promotes the reaction [SLC6A3 protein results in increased import of Dopamine]; Butyrates inhibits the reaction [Cocaine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]]; Butyrates inhibits the reaction [Mazindol inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]]; Citalopram inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Cocaine inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Cocaine inhibits the reaction [Dopamine results in increased activity of SLC6A3 protein]; Cocaine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; decamethrin inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Dextroamphetamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Fluoxetine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Ibogaine inhibits the reaction [SLC6A3 protein mutant form results in decreased import of Dopamine]; Ibogaine promotes the reaction [SLC6A3 protein results in increased import of Dopamine]; indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Ketamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; LRRK2 mutant form results in increased susceptibility to [Dopamine co-treated with SLC6A3 protein]; Mazindol inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Melitten inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS mRNA]; Methylphenidate inhibits the reaction [[Dopamine co-treated with SLC6A3 protein] results in increased expression of FOS protein]; Methylphenidate inhibits the reaction [SLC6A3 protein mutant form results in increased export of Dopamine]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; N-Methyl-3,4-methylenedioxyamphetamine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Nomifensine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; para-methyl-4-methylaminorex inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Permethrin inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]; Sulpiride inhibits the reaction [Dopamine affects the localization of SLC6A3 protein]; Sulpiride inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; vanoxerine inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; Wortmannin inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine] SLC6A3 protein polymorphism affects the uptake of Dopamine SLC6A3 protein results in increased susceptibility to Dopamine DAT protein results in increased uptake of Dopamine SLC6A3 protein affects the export of Dopamine [bisphenol A co-treated with Estradiol] inhibits the reaction [SLC6A3 protein affects the export of Dopamine]; [Cullen corylifolium extract results in decreased activity of SLC6A3 protein] which results in decreased uptake of Dopamine; [Dichlorodiphenyl Dichloroethylene co-treated with Estradiol] promotes the reaction [SLC6A3 protein affects the export of Dopamine]; bisphenol A affects the reaction [SLC6A3 protein affects the export of Dopamine]; Cocaine promotes the reaction [SLC6A3 protein affects the uptake of Dopamine]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [SLC6A3 protein affects the export of Dopamine]; Dieldrin inhibits the reaction [SLC6A3 protein affects the export of Dopamine]; Diethylstilbestrol affects the reaction [SLC6A3 protein affects the export of Dopamine]; Endosulfan inhibits the reaction [SLC6A3 protein affects the export of Dopamine]; Estradiol affects the reaction [SLC6A3 protein affects the export of Dopamine]; Modafinil inhibits the reaction [SLC6A3 protein affects the uptake of Dopamine]; nonylphenol affects the reaction [SLC6A3 protein affects the export of Dopamine] SLC6A3 protein affects the abundance of Dopamine [Chlorodiphenyl (54% Chlorine) co-treated with aroclor 1260] inhibits the reaction [SLC6A3 protein results in increased uptake of Dopamine]; [decamethrin results in increased expression of SLC6A3 protein] which results in increased uptake of Dopamine; DDT inhibits the reaction [DAT protein results in increased uptake of Dopamine]; Dichlorodiphenyl Dichloroethylene inhibits the reaction [DAT protein results in increased uptake of Dopamine]; Dichlorodiphenyldichloroethane inhibits the reaction [DAT protein results in increased uptake of Dopamine]; Heptachlor promotes the reaction [SLC6A3 protein results in increased uptake of Dopamine]; SLC6A3 mutant form affects the reaction [Cocaine affects the abundance of and affects the uptake of Dopamine]; SLC6A3 mutant form affects the reaction [Fluoxetine affects the abundance of Dopamine]; SLC6A3 mutant form promotes the reaction [Citalopram results in increased abundance of Dopamine]; SLC6A3 protein affects the reaction [[Cocaine co-treated with Alcohols] results in increased uptake of Dopamine]; SLC6A3 protein affects the reaction [Alcohols results in increased uptake of Dopamine]; SLC6A3 protein affects the reaction [Cocaine results in increased uptake of Dopamine]; SLC6A3 protein affects the reaction [Methamphetamine affects the abundance of Dopamine]; SLC6A3 protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]; vanoxerine inhibits the reaction [SLC6A3 protein promotes the reaction [1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine results in decreased abundance of Dopamine]] SLC6A3 protein results in increased transport of Dopamine
Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]
SNCA gene mutant form results in increased susceptibility to Dopamine SNCA protein results in decreased abundance of Dopamine SNCA protein affects the uptake of Dopamine [SNCA protein affects the localization of SLC6A3 protein] which affects the uptake of Dopamine; [SNCA protein co-treated with Dopamine] results in increased expression of HMOX1 protein; [SNCA protein co-treated with Paraquat co-treated with Dopamine] results in increased expression of HMOX1 protein; Dopamine inhibits the reaction [SNCA protein results in decreased abundance of Dopamine]; Dopamine inhibits the reaction [SNCA protein results in decreased abundance of Glutathione]; Dopamine inhibits the reaction [SNCA protein results in increased abundance of Thiobarbituric Acid Reactive Substances]; geraniol inhibits the reaction [SNCA protein results in decreased abundance of Dopamine]; TRAP1 protein inhibits the reaction [SNCA protein affects the abundance of Dopamine] SNCA protein results in increased abundance of Dopamine SNCA protein promotes the reaction [Rotenone results in decreased abundance of Dopamine] SNCA protein mutant form results in decreased abundance of Dopamine SNCA affects the susceptibility to Dopamine
[Copper Sulfate co-treated with Dopamine] results in decreased expression of SOD1 mRNA; [Dopamine co-treated with Dicumarol co-treated with Copper Sulfate] results in decreased expression of SOD1 mRNA Dopamine binds to SOD1 protein mutant form Dopamine results in decreased expression of SOD1 mRNA
[Dopamine results in increased expression of HMOX1 mRNA] which results in increased expression of SOD2 mRNA; Dopamine results in increased expression of SOD2 mRNA Dopamine results in decreased expression of SOD2 mRNA [Dopamine co-treated with Dicumarol co-treated with Copper Sulfate] results in decreased expression of SOD2 mRNA
Mefenamic Acid inhibits the reaction [SULT1A1 protein results in increased sulfation of Dopamine] SULT1A1 protein results in increased metabolism of Dopamine
Citalopram inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Desipramine inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; indatraline inhibits the reaction [SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; Methylphenidate inhibits the reaction [SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]]; SLC6A2 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]; SLC6A3 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]; SLC6A4 protein promotes the reaction [Dopamine results in increased activity of TAAR1 protein]
[Sulindac results in decreased activity of TDO2 protein] which results in decreased abundance of Dopamine; [Tolmetin results in decreased activity of TDO2 protein] which results in decreased abundance of Dopamine
Dopamine results in increased expression of TGFB1 mRNA DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of TGFB1 protein]; eticlopride inhibits the reaction [Dopamine results in decreased expression of TGFB1 protein]
TH protein results in increased chemical synthesis of Dopamine TH protein affects the abundance of Dopamine TH affects the abundance of Dopamine Dopamine results in decreased activity of TH protein 1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene analog promotes the reaction [TH protein results in increased chemical synthesis of Dopamine]; [1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene analog binds to and results in increased activity of HRH1 protein] promotes the reaction [TH protein results in increased chemical synthesis of Dopamine]; [Clonidine results in decreased activity of and results in decreased expression of TH protein] which results in decreased abundance of Dopamine; [Selenium deficiency results in increased activity of TH protein] which results in increased chemical synthesis of Dopamine; Cocaine promotes the reaction [[DRD2 protein results in increased phosphorylation of TH protein] which results in increased abundance of Dopamine]; dicarbine inhibits the reaction [Dopamine results in decreased activity of TH protein]; Paraquat promotes the reaction [TH protein results in increased chemical synthesis of Dopamine]; Spiperone inhibits the reaction [Cocaine promotes the reaction [[DRD2 protein results in increased phosphorylation of TH protein] which results in increased abundance of Dopamine]]; Sulpiride inhibits the reaction [Dopamine results in decreased activity of TH protein]; Triprolidine inhibits the reaction [1-phenyl-3-dimethylamino-1,2,3,4-tetrahydronaphthalene analog promotes the reaction [TH protein results in increased chemical synthesis of Dopamine]] TH protein affects the chemical synthesis of Dopamine 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine promotes the reaction [[Clozapine results in increased activity of TH protein] which results in increased metabolism of Dopamine]; [Clozapine results in increased activity of TH protein] which results in increased metabolism of Dopamine; [TH protein affects the abundance of Dopamine] which affects the susceptibility to Methamphetamine; [TH protein affects the chemical synthesis of Dopamine] which affects the susceptibility to Methamphetamine
Dopamine promotes the reaction [TNF protein results in increased expression of F3 mRNA]; TNF protein inhibits the reaction [Methamphetamine results in decreased uptake of Dopamine]; TNF protein inhibits the reaction [Methamphetamine results in increased secretion of Dopamine] vanoxerine inhibits the reaction [Dopamine analog results in increased expression of TNF protein] Dopamine results in increased expression of TNF protein Bucladesine inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Colforsin inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]; DRD2 mutant form inhibits the reaction [Dopamine results in increased expression of TNF protein]; eticlopride inhibits the reaction [Dopamine results in increased expression of TNF protein]; ICI 118551 inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Metoprolol inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]]; Propranolol inhibits the reaction [Dopamine inhibits the reaction [lipopolysaccharide, E. coli O26-B6 results in increased secretion of TNF protein]] TNF protein results in increased uptake of Dopamine
[Dopamine results in increased expression of HIF1A protein] which results in increased expression of and results in increased phosphorylation of TP53 protein [Dopamine results in increased expression of HIF1A protein] which results in increased expression of TP53 protein
Dopamine results in decreased expression of VEGFA mRNA; Dopamine results in decreased expression of VEGFA protein DRD2 mutant form inhibits the reaction [Dopamine results in decreased expression of VEGFA protein]; eticlopride inhibits the reaction [Dopamine results in decreased expression of VEGFA mRNA]; eticlopride inhibits the reaction [Dopamine results in decreased expression of VEGFA protein]
Deoxyepinephrine results in decreased expression of PRL protein Domperidone inhibits the reaction [Deoxyepinephrine results in decreased expression of PRL protein]
COMT protein results in increased chemical synthesis of Metanephrine [COMT protein results in increased methylation of Epinephrine] which results in increased abundance of Metanephrine; tolcapone inhibits the reaction [[COMT protein results in increased methylation of Epinephrine] which results in increased abundance of Metanephrine]
3-(4-t-butylphenyl)-N-(2,3-dihydrobenzo(b)(1,4)dioxin-6-yl)acrylamide inhibits the reaction [N-oleoyldopamine promotes the reaction [TRPV1 protein results in increased uptake of Calcium]]; [N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium; iodoresiniferatoxin inhibits the reaction [[N-oleoyldopamine results in increased activity of TRPV1 protein] which results in increased uptake of Calcium]; iodoresiniferatoxin inhibits the reaction [N-oleoyldopamine results in increased activity of TRPV1 protein]
Oxidopamine results in increased expression of ACO1 mRNA ACO1 protein affects the susceptibility to Oxidopamine [ACO1 protein affects the susceptibility to Oxidopamine] which results in decreased expression of HEPH mRNA; Oxidopamine promotes the reaction [ACO1 protein results in decreased expression of SLC40A1 mRNA]
8-(3-chlorostyryl)caffeine inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of ADORA2A protein]; [Oxidopamine co-treated with Levodopa] results in increased expression of ADORA2A mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of ADORA2A protein
alpha-iso-cubebenol inhibits the reaction [Oxidopamine affects the localization of AIFM1 protein]; Selegiline inhibits the reaction [Oxidopamine affects the localization of AIFM1 protein] Oxidopamine results in increased expression of AIFM1 protein
Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]; Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]; Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT1 protein]; Oxidopamine results in increased phosphorylation of and results in increased activity of AKT1 protein Oxidopamine affects the phosphorylation of AKT1 protein 2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of AKT1 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine affects the phosphorylation of AKT1 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of AKT1 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [Oxidopamine affects the phosphorylation of AKT1 protein]; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of AKT1 protein
Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein]; Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein]; Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT2 protein]
Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]; Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]; Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of AKT3 protein]
Oxidopamine results in increased expression of ATF4 mRNA; Oxidopamine results in increased expression of ATF4 protein Resveratrol inhibits the reaction [Oxidopamine results in increased expression of ATF4 protein]
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of ATXN2 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of ATXN2 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of ATXN2 mRNA]
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of ATXN3 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of ATXN3 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of ATXN3 mRNA]
Oxidopamine affects the localization of BAX protein Oxidopamine results in increased expression of BAX protein 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride inhibits the reaction [Oxidopamine results in increased expression of BAX protein]; Resveratrol inhibits the reaction [Oxidopamine results in increased expression of BAX protein]; Tea inhibits the reaction [Oxidopamine results in increased expression of BAX protein] aureusidin inhibits the reaction [Oxidopamine results in increased expression of BAX mRNA]; aureusidin inhibits the reaction [Oxidopamine results in increased expression of BAX protein]; tricetin inhibits the reaction [Oxidopamine results in increased expression of BAX mRNA]; tricetin inhibits the reaction [Oxidopamine results in increased expression of BAX protein]; Valproic Acid inhibits the reaction [Oxidopamine results in increased expression of BAX protein] Oxidopamine results in increased expression of BAX mRNA; Oxidopamine results in increased expression of BAX protein
aureusidin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 mRNA]; aureusidin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]]; pyrazolanthrone inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; SB 203580 inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; tricetin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 mRNA]; tricetin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein] Oxidopamine results in decreased expression of BCL2 mRNA; Oxidopamine results in decreased expression of BCL2 protein 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]; Tea inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein] [2-chloro-5-hydroxyphenylglycine co-treated with Oxidopamine] results in decreased expression of BCL2 protein; [6-methyl-2-(phenylethynyl)pyridine co-treated with Oxidopamine] results in decreased expression of BCL2 protein
Oxidopamine results in decreased expression of BDNF protein chrysin inhibits the reaction [Oxidopamine results in decreased expression of BDNF protein]
Oxidopamine results in increased cleavage of CASP12 protein Resveratrol inhibits the reaction [Oxidopamine results in increased cleavage of CASP12 protein]
Oxidopamine results in increased activity of CASP3 protein Oxidopamine results in increased cleavage of CASP3 protein aureusidin inhibits the reaction [Oxidopamine results in increased cleavage of and results in increased activity of CASP3 protein]; Caffeine inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; ginsenoside Rb1 inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; MIR107 mRNA affects the reaction [Oxidopamine affects the activity of CASP3 protein]; OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; Oxidopamine results in increased cleavage of and results in increased activity of CASP3 protein; Oxidopamine results in increased expression of and results in increased activity of CASP3 protein; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; pinostilbene inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; Plant Extracts inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; puag-haad inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; Resveratrol inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; SB 203580 inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; sulforaphane inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; tricetin inhibits the reaction [Oxidopamine results in increased expression of and results in increased activity of CASP3 protein]; Valproic Acid inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein] 3-methyladenine inhibits the reaction [Oxidopamine results in increased expression of CASP3 protein modified form]; 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; Emodin inhibits the reaction [Oxidopamine results in decreased expression of and results in increased cleavage of CASP3 protein]; Emodin inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of CASP3 mRNA]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Oxidopamine results in increased activity of CASP3 protein]; MDL 201053 inhibits the reaction [Oxidopamine results in increased expression of CASP3 protein modified form]; MIR107 mRNA affects the reaction [Oxidopamine affects the activity of CASP3 protein]; Oxidopamine results in decreased expression of and results in increased cleavage of CASP3 protein; Resveratrol inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]; Rutin inhibits the reaction [Oxidopamine results in increased expression of CASP3 mRNA]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein] Oxidopamine results in increased expression of CASP3 mRNA; Oxidopamine results in increased expression of CASP3 protein modified form
Levodopa inhibits the reaction [Oxidopamine results in increased expression of CASP7 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of CASP7 mRNA] Valproic Acid inhibits the reaction [Oxidopamine results in increased cleavage of CASP7 protein]
Oxidopamine results in increased activity of CASP9 protein Oxidopamine results in increased cleavage of CASP9 protein sulforaphane inhibits the reaction [Oxidopamine results in increased activity of CASP9 protein]; Valproic Acid inhibits the reaction [Oxidopamine results in increased cleavage of CASP9 protein]
Oxidopamine results in decreased activity of CAT protein aureusidin inhibits the reaction [Oxidopamine results in decreased activity of CAT protein] Tea inhibits the reaction [Oxidopamine results in decreased activity of CAT protein]
Oxidopamine results in increased expression of CYCS protein aureusidin inhibits the reaction [Oxidopamine results in increased expression of and affects the localization of CYCS protein]; Oxidopamine results in increased expression of and affects the localization of CYCS protein
Oxidopamine results in increased expression of DDIT3 mRNA; Oxidopamine results in increased expression of DDIT3 protein Resveratrol inhibits the reaction [Oxidopamine results in increased expression of DDIT3 protein]; sodium bisulfide inhibits the reaction [Oxidopamine results in increased expression of DDIT3 protein]
Oxidopamine affects the localization of DLG1 protein Oxidopamine results in decreased expression of DLG1 protein [Oxidopamine co-treated with Levodopa] results in increased expression of DLG1 mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of DLG1 protein
[Oxidopamine co-treated with Levodopa] results in increased expression of DLG4 mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of DLG4 protein; Resveratrol inhibits the reaction [Oxidopamine results in decreased expression of DLG4 protein] Oxidopamine results in decreased expression of DLG4 mRNA; Oxidopamine results in decreased expression of DLG4 protein Oxidopamine affects the localization of DLG4 protein
Oxidopamine affects the localization of DNM1L protein Oxidopamine results in increased expression of DNM1L protein 3-(2,4-dichloro-5-methoxyphenyl)-2-sulfanyl-4(3H)-quinazolinone inhibits the reaction [Oxidopamine affects the localization of DNM1L protein]
[Levodopa co-treated with Oxidopamine] results in increased expression of DRD1 mRNA; [Oxidopamine co-treated with levodopa methyl ester] promotes the reaction [Benserazide results in increased expression of DRD1 protein]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of DRD1 protein] Oxidopamine results in increased expression of DRD1 protein Oxidopamine results in decreased expression of DRD1 mRNA; Oxidopamine results in decreased expression of DRD1 protein
[Oxidopamine co-treated with levodopa methyl ester] inhibits the reaction [Benserazide results in increased expression of DRD2 protein]; Dopamine promotes the reaction [Oxidopamine binds to DRD2 protein]; Tea inhibits the reaction [Dopamine promotes the reaction [Oxidopamine binds to DRD2 protein]] Oxidopamine results in increased expression of DRD2 mRNA; Oxidopamine results in increased expression of DRD2 protein
[Levodopa co-treated with Oxidopamine] results in increased expression of DRD3 mRNA; [Levodopa co-treated with Oxidopamine] results in increased expression of DRD3 protein; Oxidopamine inhibits the reaction [7-hydroxy-2-N,N-dipropylaminotetralin binds to DRD3 protein] Oxidopamine results in decreased expression of DRD3 mRNA
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of EGLN1 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of EGLN1 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of EGLN1 mRNA]
EIF2AK3 protein affects the susceptibility to Oxidopamine Oxidopamine results in increased phosphorylation of and results in increased activity of EIF2AK3 protein
[Levodopa co-treated with Oxidopamine] results in increased expression of FOS protein; [Oxidopamine co-treated with Levodopa] results in increased expression of FOS mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of FOS protein; GDNF protein inhibits the reaction [Oxidopamine inhibits the reaction [Amphetamine results in increased expression of FOS protein]]; Oxidopamine inhibits the reaction [Amphetamine results in increased expression of FOS protein] Oxidopamine results in decreased expression of FOS protein
[Levodopa co-treated with Oxidopamine] results in increased expression of FOSB protein; [Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein Oxidopamine results in increased expression of FOSB protein 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Levodopa co-treated with Oxidopamine] results in increased expression of FOSB protein]; [Levodopa co-treated with Oxidopamine] results in increased expression of FOSB protein; [Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein]; Levodopa promotes the reaction [Oxidopamine results in increased expression of FOSB protein]
6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of GAD1 mRNA]]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of GAD1 mRNA]; Levodopa promotes the reaction [Oxidopamine results in increased expression of GAD1 mRNA]
[TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein]; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; [TH co-treated with GCH1] inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]]
Oxidopamine results in decreased expression of GCLC protein salvin inhibits the reaction [Oxidopamine results in decreased expression of GCLC protein] Oxidopamine results in increased expression of GCLC mRNA; Oxidopamine results in increased expression of GCLC protein
Oxidopamine results in decreased expression of GCLM protein Oxidopamine results in increased expression of GCLM mRNA salvin inhibits the reaction [Oxidopamine results in decreased expression of GCLM protein] AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]]; fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of GCLM protein]
GDNF protein affects the susceptibility to Oxidopamine Oxidopamine results in decreased expression of GDNF protein chrysin inhibits the reaction [Oxidopamine results in decreased expression of GDNF protein] GDNF protein affects the susceptibility to [Apomorphine co-treated with Oxidopamine]; GDNF protein affects the susceptibility to [Dextroamphetamine co-treated with Oxidopamine]; GDNF protein affects the susceptibility to [Oxidopamine co-treated with Amphetamine]; GDNF protein affects the susceptibility to [Oxidopamine co-treated with Dextroamphetamine]; GDNF protein inhibits the reaction [Oxidopamine inhibits the reaction [Amphetamine results in increased expression of FOS protein]] GDNF protein inhibits the reaction [Oxidopamine results in decreased secretion of Dopamine]
Oxidopamine results in decreased expression of GFAP protein Oxidopamine results in increased expression of GFAP protein Resveratrol inhibits the reaction [Oxidopamine results in increased expression of GFAP protein]; Rosiglitazone promotes the reaction [Oxidopamine results in increased expression of GFAP protein]
Oxidopamine affects the expression of GOPC protein 2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the expression of TH protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the expression of TH protein]; [GOPC protein affects the susceptibility to Oxidopamine] which affects the expression of TH protein 2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of AKT1 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK3 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK8 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine affects the expression of GOPC protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of AKT1 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK3 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK8 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [Oxidopamine affects the expression of GOPC protein]; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of AKT1 protein; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK3 protein; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK8 protein; GOPC protein affects the reaction [2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; GOPC protein affects the reaction [6-methyl-2-(phenylethynyl)pyridine promotes the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; GOPC protein affects the reaction [Oxidopamine results in increased cleavage of PARP1 protein]
Oxidopamine results in decreased expression of GRIN1 mRNA; Oxidopamine results in decreased expression of GRIN1 protein alternative form Levodopa inhibits the reaction [Oxidopamine results in decreased expression of GRIN1 protein alternative form]
Oxidopamine results in decreased expression of GSR protein salvin inhibits the reaction [Oxidopamine results in decreased expression of GSR protein] sulforaphane inhibits the reaction [Oxidopamine results in decreased activity of GSR protein]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein]]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein]]; GSTP1 mutant form inhibits the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of GSTP1 protein]
Oxidopamine results in decreased expression of HEPH mRNA; Oxidopamine results in decreased expression of HEPH protein [ACO1 protein affects the susceptibility to Oxidopamine] which results in decreased expression of HEPH mRNA; [IREB2 protein affects the susceptibility to Oxidopamine] which results in decreased expression of HEPH mRNA
Oxidopamine affects the expression of HES1 protein MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]
AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]]; fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]; N-(4-O-glycerol-3-methoxybenzyl)nonivamide inhibits the reaction [Oxidopamine results in decreased expression of HMOX1 protein]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]] Oxidopamine results in increased expression of HMOX1 mRNA; Oxidopamine results in increased expression of HMOX1 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]; [5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride results in decreased abundance of Peroxynitrous Acid] inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]; Acetylcysteine inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]; N-(3-(aminomethyl)benzyl)acetamidine inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]; U 0126 inhibits the reaction [Oxidopamine results in increased expression of HMOX1 protein]
Oxidopamine results in increased expression of HSPA5 mRNA; Oxidopamine results in increased expression of HSPA5 protein Resveratrol inhibits the reaction [Oxidopamine results in increased expression of HSPA5 protein]; sodium bisulfide inhibits the reaction [Oxidopamine results in increased expression of HSPA5 protein]
Oxidopamine results in decreased expression of HTR1A mRNA stepholidine inhibits the reaction [Oxidopamine results in decreased expression of HTR1A mRNA]
Oxidopamine results in increased expression of IFNG protein chrysin inhibits the reaction [Oxidopamine results in increased expression of IFNG protein]
chrysin inhibits the reaction [Oxidopamine results in increased expression of IL1B protein] Resveratrol inhibits the reaction [Oxidopamine results in increased expression of IL1B protein]
Oxidopamine results in increased expression of IREB2 mRNA [IREB2 protein affects the susceptibility to Oxidopamine] which results in decreased expression of HEPH mRNA; Oxidopamine promotes the reaction [IREB2 protein results in decreased expression of SLC40A1 mRNA]
Apomorphine inhibits the reaction [Oxidopamine results in increased phosphorylation of JUN protein]; pinostilbene inhibits the reaction [Oxidopamine results in increased phosphorylation of JUN protein]; puag-haad inhibits the reaction [Oxidopamine results in increased phosphorylation of JUN protein] Acetylcysteine inhibits the reaction [Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]]; Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]
[Oxidopamine co-treated with Levodopa] results in increased expression of JUNB mRNA; Dizocilpine Maleate inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of JUNB mRNA]; eticlopride affects the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of JUNB mRNA]; Oxidopamine results in increased localization of and results in increased activity of JUNB protein
Oxidopamine results in increased phosphorylation of MAPK1 protein Oxidopamine affects the phosphorylation of MAPK1 protein Oxidopamine results in increased phosphorylation of and results in increased activity of MAPK1 protein 2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine affects the phosphorylation of MAPK1 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [Oxidopamine affects the phosphorylation of MAPK1 protein]; [benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK1 protein; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK1 protein; [Levodopa co-treated with Oxidopamine] results in increased phosphorylation of MAPK1 protein; [Oxidopamine co-treated with Levodopa] results in increased expression of MAPK1 protein; [Oxidopamine co-treated with Levodopa] results in increased phosphorylation of MAPK1 protein; SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of MAPK1 protein]; SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK1 protein]; sulforaphane inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein] 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]; AL 8810 inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]; alpha-iso-cubebenol inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]; fluprostenol promotes the reaction [Oxidopamine results in increased phosphorylation of MAPK1 protein]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein]; AL 8810 inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein]; alpha-iso-cubebenol inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein]; fluprostenol promotes the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein] Oxidopamine affects the phosphorylation of MAPK3 protein Oxidopamine results in increased phosphorylation of and results in increased activity of MAPK3 protein 2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK3 protein]; 2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine affects the phosphorylation of MAPK3 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK3 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [Oxidopamine affects the phosphorylation of MAPK3 protein]; [benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK3 protein; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK3 protein; [Levodopa co-treated with Oxidopamine] results in increased phosphorylation of MAPK3 protein; [Oxidopamine co-treated with Levodopa] results in increased expression of MAPK3 protein; [Oxidopamine co-treated with Levodopa] results in increased phosphorylation of MAPK3 protein; SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of MAPK3 protein]; SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of MAPK3 protein]; sulforaphane inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK3 protein]
Oxidopamine results in increased phosphorylation of MAPK8 protein salvin inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein] puag-haad inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]; tricetin inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein] 2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK8 protein]; 2-chloro-5-hydroxyphenylglycine promotes the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK8 protein]; 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK8 protein]; [GOPC protein affects the susceptibility to Oxidopamine] which affects the phosphorylation of MAPK8 protein; Acetylcysteine inhibits the reaction [Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]]; manganese(III)-tetrakis(4-benzoic acid)porphyrin inhibits the reaction [Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]]; Oxidopamine promotes the reaction [MAPK8 protein binds to and results in increased phosphorylation of JUN protein]
Oxidopamine results in increased phosphorylation of MAPK9 protein salvin inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK9 protein] puag-haad inhibits the reaction [Oxidopamine results in increased phosphorylation of MAPK9 protein]
Oxidopamine results in decreased expression of MIR107 mRNA [Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]] which affects the expression of PDCD10 mRNA; [Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]] which affects the expression of PDCD10 protein; MIR107 mRNA affects the reaction [Oxidopamine affects the activity of CASP3 protein]; MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]; MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]; Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]] MIR107 mRNA affects the reaction [Oxidopamine affects the activity of CASP3 protein]; MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]; MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]]
[Oxidopamine co-treated with Celecoxib] results in increased expression of MITF mRNA; Oxidopamine promotes the reaction [Celecoxib results in increased expression of MITF mRNA]
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased expression of MMP9 mRNA]; Acetylcysteine inhibits the reaction [Oxidopamine results in increased expression of MMP9 mRNA]; SB 203580 inhibits the reaction [Oxidopamine results in increased expression of MMP9 mRNA]
2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine affects the localization of NFE2L2 protein]; [2-tert-butylhydroquinone results in increased expression of NFE2L2 protein] which results in decreased susceptibility to Oxidopamine; [linsidomine results in increased expression of NFE2L2 protein] which results in decreased susceptibility to Oxidopamine; AL 8810 inhibits the reaction [Oxidopamine affects the localization of NFE2L2 protein] Oxidopamine results in decreased expression of NFE2L2 protein Oxidopamine results in increased localization of NFE2L2 protein Oxidopamine results in increased expression of NFE2L2 mRNA; Oxidopamine results in increased expression of NFE2L2 protein Oxidopamine results in increased activity of NFE2L2 protein 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased expression of NFE2L2 protein]; 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one inhibits the reaction [Oxidopamine results in increased localization of NFE2L2 protein] NFE2L2 protein results in decreased susceptibility to Oxidopamine
Oxidopamine results in increased expression of NOS2 protein [Oxidopamine results in increased expression of NOS2 protein] which results in increased secretion of Nitrites N-(4-O-glycerol-3-methoxybenzyl)nonivamide inhibits the reaction [Oxidopamine results in increased expression of NOS2 protein]
MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]]
Oxidopamine results in increased expression of NQO1 mRNA; Oxidopamine results in increased expression of NQO1 protein AL 8810 inhibits the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]]; fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]]
Oxidopamine results in decreased expression of NSF mRNA isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of NSF mRNA]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of NSF mRNA]; Rutin inhibits the reaction [Oxidopamine results in decreased expression of NSF mRNA]
Oxidopamine results in decreased expression of NSG1 mRNA isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of NSG1 mRNA]; Rutin inhibits the reaction [Oxidopamine results in decreased expression of NSG1 mRNA]
isoquercitrin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of OPA1 mRNA]; Rutin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 mRNA] Oxidopamine results in decreased expression of OPA1 protein OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of OPA1 protein]
Oxidopamine promotes the reaction [Quinones binds to PARK7 protein] Oxidopamine results in increased expression of PARK7 mRNA [4-phenylbutyric acid results in increased expression of PARK7 protein] which results in decreased susceptibility to Oxidopamine; isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PARK7 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of PARK7 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of PARK7 mRNA] PARK7 protein results in decreased susceptibility to Oxidopamine Oxidopamine results in increased expression of PARK7 mRNA; Oxidopamine results in increased expression of PARK7 protein Oxidopamine affects the localization of PARK7 protein
aureusidin inhibits the reaction [Oxidopamine affects the cleavage of PARP1 protein]; OPA1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; pyrazolanthrone inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; SB 203580 inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; TH protein inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; tricetin inhibits the reaction [Oxidopamine results in increased expression of PARP1 protein] 5,10,15,20-tetrakis(4-sulfonatophenyl)porphyrinato iron(III) chloride inhibits the reaction [Oxidopamine results in increased activity of PARP1 protein]; salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein] 2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; 6-methyl-2-(phenylethynyl)pyridine promotes the reaction [Oxidopamine results in increased cleavage of PARP1 protein]; GOPC protein affects the reaction [2-chloro-5-hydroxyphenylglycine affects the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; GOPC protein affects the reaction [6-methyl-2-(phenylethynyl)pyridine promotes the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; GOPC protein affects the reaction [Oxidopamine results in increased cleavage of PARP1 protein]
PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]] [Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]] which affects the expression of PDCD10 mRNA; [Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]] which affects the expression of PDCD10 protein; Oxidopamine affects the reaction [MIR107 mRNA binds to PDCD10 3' UTR]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of HES1 protein]]; PDCD10 protein affects the reaction [MIR107 mRNA affects the reaction [Oxidopamine affects the expression of NOTCH1 protein]]
[Levodopa co-treated with Oxidopamine] results in increased expression of PDYN mRNA; [Levodopa co-treated with Oxidopamine] results in increased expression of PDYN protein; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of PDYN mRNA] Oxidopamine results in increased expression of PDYN mRNA 6-methyl-2-(phenylethynyl)pyridine inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; [Levodopa co-treated with Oxidopamine] results in increased expression of PDYN mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of PDYN protein; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; Corticosterone inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; IEM 1460 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of PDYN mRNA]
[Oxidopamine co-treated with Levodopa] results in increased expression of PENK mRNA Oxidopamine results in increased expression of PENK mRNA; Oxidopamine results in increased expression of PENK protein [Levodopa co-treated with Oxidopamine] results in increased expression of PENK mRNA; [Oxidopamine co-treated with Levodopa] results in increased expression of PENK mRNA; [TH co-treated with GCH1] inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]]; Corticosterone inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PENK mRNA]; IEM 1460 inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]]; Isradipine inhibits the reaction [Oxidopamine results in increased expression of PENK mRNA]; Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]; S 33084 inhibits the reaction [[Levodopa co-treated with Oxidopamine] results in increased expression of PENK mRNA]
Oxidopamine results in decreased expression of PINK1 protein PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of BCL2 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of VDAC1 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of CASP3 protein]]; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of PINK1 protein]
Oxidopamine results in decreased expression of PPARGC1A protein LY 344864 inhibits the reaction [Oxidopamine results in decreased expression of PPARGC1A protein]
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PPID mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of PPID mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of PPID mRNA]
[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of PPP1R1B protein [Oxidopamine co-treated with Levodopa] affects the phosphorylation of PPP1R1B protein
Clenbuterol inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein]; Colforsin inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein]; Dobutamine inhibits the reaction [Oxidopamine results in decreased phosphorylation of PRKACA protein]
Oxidopamine results in increased cleavage of and results in increased activity of PRKCD protein PRKCD protein results in increased susceptibility to Oxidopamine benzoylcarbonyl-aspartyl-glutamyl-valyl-aspartyl-fluoromethyl ketone inhibits the reaction [Oxidopamine results in increased cleavage of and results in increased activity of PRKCD protein]; Oxidopamine results in increased cleavage of and results in increased activity of PRKCD protein
PRKN protein inhibits the reaction Oxidopamine Oxidopamine affects the expression of PRKN protein alternative form Oxidopamine results in decreased expression of PRKN protein PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of PRKN protein]; Tretinoin affects the reaction [Oxidopamine affects the expression of PRKN protein alternative form] PRKN protein inhibits the reaction [Oxidopamine results in decreased expression of TH protein] Oxidopamine results in increased expression of PRKN mRNA isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of PRKN mRNA]
Oxidopamine results in increased expression of PTGFR protein PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of GCLM mRNA]]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of HMOX1 mRNA]]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of NQO1 mRNA]]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of TXNRD1 mRNA]]
N-(4-O-glycerol-3-methoxybenzyl)nonivamide inhibits the reaction [Oxidopamine results in increased expression of PTGS2 protein] rosiglitazone inhibits the reaction [Oxidopamine results in increased expression of PTGS2 protein] Oxidopamine results in increased expression of PTGS2 mRNA; Oxidopamine results in increased expression of PTGS2 protein
[Levodopa co-treated with Oxidopamine] affects the expression of RASGRP1 mRNA; [Levodopa co-treated with Oxidopamine] affects the expression of RASGRP1 protein
Oxidopamine results in increased localization of and results in increased activity of RELA protein; SN50 peptide inhibits the reaction [Oxidopamine results in increased localization of RELA protein] N-(1-(4-(5-chloro-2-oxo-2,3-dihydro-1H-benzo(d)imidazol-1-yl)piperidin-1-yl)propan-2-yl)-2-naphthamide inhibits the reaction [Oxidopamine affects the localization of RELA protein] chrysin inhibits the reaction [Oxidopamine results in increased phosphorylation of RELA protein] Oxidopamine results in increased activity of RELA protein
[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of RPS6KA5 protein; [Oxidopamine co-treated with Levodopa] results in increased expression of RPS6KA5 protein; SCH 23390 inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of RPS6KA5 protein]; SL 327 inhibits the reaction [[benserazide, levodopa drug combination co-treated with Oxidopamine] results in increased phosphorylation of RPS6KA5 protein]
SHH protein modified form affects the susceptibility to [Apomorphine co-treated with Oxidopamine]; SHH protein modified form affects the susceptibility to [Dextroamphetamine co-treated with Oxidopamine]
Oxidopamine results in decreased expression of SLC18A2 mRNA Resveratrol inhibits the reaction [Oxidopamine results in decreased expression of SLC18A2 protein]
Oxidopamine promotes the reaction [ACO1 protein results in decreased expression of SLC40A1 mRNA]; Oxidopamine promotes the reaction [IREB2 protein results in decreased expression of SLC40A1 mRNA] Oxidopamine results in decreased expression of SLC40A1 mRNA; Oxidopamine results in decreased expression of SLC40A1 protein
Oxidopamine results in decreased expression of SLC6A3 mRNA; Oxidopamine results in decreased expression of SLC6A3 protein Oxidopamine results in increased secretion of SLC6A3 protein Resveratrol inhibits the reaction [Oxidopamine results in increased expression of SLC6A3 protein] SLC6A3 protein results in increased susceptibility to Oxidopamine Oxidopamine results in increased expression of SLC6A3 mRNA; Oxidopamine results in increased expression of SLC6A3 protein
Oxidopamine results in increased expression of SNCA mRNA alternative form Oxidopamine results in increased expression of SNCA protein SNCA protein mutant form results in increased susceptibility to Oxidopamine
salvin inhibits the reaction [Oxidopamine results in decreased expression of SOD1 protein] Oxidopamine results in decreased expression of SOD1 mRNA; Oxidopamine results in decreased expression of SOD1 protein
Oxidopamine promotes the reaction [SQSTM1 protein binds to and results in decreased activity of SQSTM1 protein] Oxidopamine results in decreased expression of SQSTM1 protein
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of STUB1 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of STUB1 mRNA]
[Oxidopamine co-treated with Celecoxib] results in increased expression of TFEB mRNA; Oxidopamine promotes the reaction [Celecoxib results in increased expression of TFEB mRNA]
TH protein affects the susceptibility to Oxidopamine 2-chloro-5-hydroxyphenylglycine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the expression of TH protein]; 3-methyladenine inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; 6-methyl-2-(phenylethynyl)pyridine affects the reaction [[GOPC protein affects the susceptibility to Oxidopamine] which affects the expression of TH protein]; [GOPC protein affects the susceptibility to Oxidopamine] which affects the expression of TH protein; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of FOSB protein]; [TH co-treated with GCH1] inhibits the reaction [[Oxidopamine co-treated with Levodopa] results in increased expression of PDYN mRNA]; [TH co-treated with GCH1] inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in increased expression of PENK mRNA]]; Drugs, Chinese Herbal inhibits the reaction [Levodopa promotes the reaction [Oxidopamine results in decreased expression of TH mRNA]]; isoquercitrin promotes the reaction [Oxidopamine results in decreased expression of TH mRNA]; Levodopa inhibits the reaction [Oxidopamine results in decreased expression of TH mRNA]; Levodopa promotes the reaction [Oxidopamine results in decreased expression of TH mRNA]; MDL 201053 inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; Resveratrol inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; Rosiglitazone inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; Rutin inhibits the reaction [Oxidopamine results in decreased expression of TH mRNA]; salvin inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; Tea inhibits the reaction [Oxidopamine results in decreased expression of TH mRNA]; Tea inhibits the reaction [Oxidopamine results in decreased expression of TH protein] Oxidopamine results in decreased expression of TH mRNA; Oxidopamine results in decreased expression of TH protein LY 344864 inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; PRKN protein inhibits the reaction [Oxidopamine results in decreased expression of TH protein]; sulforaphane inhibits the reaction [Oxidopamine results in decreased expression of TH protein] TH protein inhibits the reaction [Oxidopamine results in increased cleavage of PARP1 protein]
Oxidopamine results in decreased expression of TIMP2 mRNA; Oxidopamine results in decreased expression of TIMP2 protein TIMP2 protein results in decreased susceptibility to Oxidopamine
Oxidopamine results in increased expression of TNF protein chrysin inhibits the reaction [Oxidopamine results in increased expression of TNF protein] Resveratrol inhibits the reaction [Oxidopamine results in increased expression of TNF protein]; Rosiglitazone inhibits the reaction [Oxidopamine results in increased expression of TNF protein]
[Levodopa co-treated with Oxidopamine] results in increased expression of TRH mRNA; [Levodopa co-treated with Oxidopamine] results in increased expression of TRH protein
fluprostenol promotes the reaction [Oxidopamine results in increased expression of TXNRD1 mRNA]; PTGFR protein affects the reaction [fluprostenol promotes the reaction [Oxidopamine results in increased expression of TXNRD1 mRNA]]
isoquercitrin inhibits the reaction [Oxidopamine results in increased expression of UCHL1 mRNA]; Levodopa inhibits the reaction [Oxidopamine results in increased expression of UCHL1 mRNA]; Rutin inhibits the reaction [Oxidopamine results in increased expression of UCHL1 mRNA]
Oxidopamine results in decreased expression of and results in decreased ubiquitination of VDAC1 protein; PINK1 protein affects the reaction [salvin inhibits the reaction [Oxidopamine results in decreased expression of VDAC1 protein]]; salvin inhibits the reaction [Oxidopamine results in decreased expression of and results in decreased ubiquitination of VDAC1 protein]
browse the term
